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Abstract 
 
 Type 1 diabetes is a chronic incurable autoimmune disease characterized by dysregulated 
carbohydrate metabolism. Nearly 3 million individuals in the United States with type 1 diabetes 
are challenged to meticulous self-management to avoid diabetes-related complications. 
Self-efficacy is an important construct associated with health behavior change that may be 
relevant for adherence to diabetes self-management tasks involving diabetes technologies, such 
as continuous glucose monitoring (CGM). Yet, there is a fundamental gap in understanding how 
self-efficacy relates to CGM use in youth with type 1 diabetes. This dissertation focuses on the 
behavior of CGM use in youth with type 1 diabetes as well as the relationship of self-efficacy 
and self-management adherence in the contemporary era of diabetes technologies. Specifically, 
the following research questions are addressed: (a) how do masked CGM and treatment 
recommendations following sensor wear affect glycemic control in a contemporary cohort of 
youth with type 1 diabetes, (b) what instruments are available to measure self-efficacy related to 
contemporary diabetes management in youth with type 1 diabetes and their caregivers, (c) how 
does self-efficacy, measured by a novel CGM Self-Efficacy instrument (CGM-SE), relate to 
CGM use and glycemic control in a cohort of youth with type 1 diabetes initiating CGM therapy. 
The conclusions from this research are that: (a) masked CGM offers opportunities to guide 
advanced insulin management and requires orchestration of the multidisciplinary diabetes team, 
particularly nurse educators, (b) an integrative review identified 10 different instruments to 
measure self-efficacy related to diabetes management with varying levels of reliability and 
validity, yet there is a deficit in available instruments to measure self-efficacy related to diabetes 
technologies such as CGM, (c) a novel CGM-SE instrument used in a contemporary cohort of 
youth with type 1 diabetes appears to have strong psychometric properties and demonstrated 
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predictive validity as youth that reported higher baseline self-efficacy had significantly greater 
CGM wear and lower hemoglobin A1c (HbA1c) at 3 and 6 months compared to youth reporting 
lower self-efficacy. This body of work provides a greater understanding of the use of masked 
CGM technology, the concept of self-efficacy as it relates to youth with type 1 diabetes and their 
caregivers, and how to measure self-efficacy related to CGM use in a contemporary cohort of 
youth with type 1 diabetes. Importantly, this dissertation refines the relationship between self-
efficacy and CGM use by establishing the utility of the CGM-SE instrument. Identifying 
elements, such as self-efficacy, that may promote and improve self-management behaviors is an 
important step towards improving diabetes outcomes and consistent use of CGM technology. 
This is especially relevant to diabetes nurse educators who play a critical role in supporting the 
self-management of youth with type 1 diabetes and their families. 
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Chapter 1: Introduction 
Knowledge in the Field of Study 
To date, there is no cure for type 1 diabetes, a chronic disease affecting around 3 million 
people in the United States.1 While ongoing research focuses on the etiology of type 1 diabetes, 
additional efforts must concentrate on improving diabetes self-care and glycemic control through 
the use of technology as well as attributes, such as self-efficacy, that may promote adherence. 
Technological advances, such as continuous glucose monitoring (CGM), continue to refine 
diabetes self-care management yet can increase patient burden by an increased awareness and 
attention to diabetes tasks. Masked CGM is a retrospective form of Real-Time CGM (RT-CGM) 
without the burden of sensor alarms. Although studies have demonstrated the clinical utility of 
the masked CGM device; information on device implementation in the pediatric setting as well 
as the treatment recommendations generated and impact on hemoglobin A1c (HbA1c) following 
masked CGM wear in today’s youth with type 1 diabetes is limited. Investigating psychosocial 
factors, such as self-efficacy, and implications of this intensive disease management are essential 
for nurse educators to effectively educate and support patients with type 1 diabetes in successful 
disease outcomes in the era of diabetes technologies. The value of self-efficacy research in the 
efforts to improve youth glycemic control and type 1 diabetes self-management should not be 
undermined. Although there is extensive literature on self-efficacy and different factors of 
diabetes management in type 1 diabetes youth as well as the importance of self-efficacy in 
promoting general health behaviors of adolescents, there is a gap in how self-efficacy relates to 
or predicts CGM use in type 1 diabetes among youth. A focus of this dissertation is to adequately 
address the knowledge gaps of masked CGM use and self-efficacy related to CGM technology in 
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youth with type 1 diabetes; such research approaches must occur within a comprehensive 
understanding of type 1 diabetes epidemiology, pathophysiology, and disease management. 
Type 1 Diabetes Overview 
Epidemiology 
The diagnosis of type 1 diabetes often penetrates a child and family’s life without 
warning, adding layers of complexity to the normal stages of childhood growth and 
development. Classified as an autoimmune condition, type 1 diabetes in youth typically affects 
patients under 18 years of age.2 Type 1 diabetes affects an estimated 3 million people in the 
United States with an estimated incidence of over 18,000 youth diagnosed.1 Globally, 78,000 
youth are diagnosed with type 1 diabetes each year; yet the worldwide prevalence data are not 
known.1 Despite the growing understanding of type 1 diabetes as a national and global public 
health challenge, the etiology of this chronic condition remains unknown.2 First-degree relatives 
have an estimated 5% risk of developing type 1 diabetes;1 this relatively modest percentage 
leaves many families wondering how the disease could affect children without a prior family 
history. Type 1 diabetes can occur throughout the lifespan; however, there are certain time points 
that are associated with an increased chance of disease development. The likelihood of type 1 
diabetes developing in youth peaks between the ages of 10-14 years3 and is likely related to the 
insulin resistance associated with the hormonal surges during puberty. Recent reports from 
different countries suggest that the incidence of type 1 diabetes may be leveling off3-5 yet 
continued research focused on identifying the cause of type 1 diabetes is warranted. As with 
many health related conditions, genetic and environmental factors are thought to influence 
development of this chronic disease.6 
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Pathophysiology 
Type 1 diabetes is an autoimmune disorder characterized by the destruction of pancreatic 
β cells, which leads to dysregulated insulin/glucagon production and an inability to sustain 
normal glucose metabolism. The loss of the body’s ability to regulate and maintain glucose 
levels results in a subsequent dependence on exogenous insulin for survival.1,2,6 The usual 
clinical signs and symptoms indicative of a diagnosis of type 1 diabetes consist of 
hyperglycemia, polydipsia, polyuria, and weight loss as well as the presence of positive 
pancreatic autoantibodies.1 The Diabetes Control and Complications Trial (DCCT) was a 
landmark randomized clinical trial (RCT) that set the precedence for intensive therapy (e.g. 
multiple daily injections or insulin pump therapy) in people with type 1 diabetes to maintain 
euglycemia to mitigate the risk of long-term micro- and macrovascular complications.7  
The literature describes potential environmental triggers that may influence the 
development of type 1 diabetes, including cow’s milk protein exposure, vitamin D deficiency 
and viral infections including coxsackie, Epstein-Barr, and the enterovirus.6 Additional research 
on possible environmental causes suggests that microbial stimuli such as mycobacteria may be a 
protective factor related to the development of type 1 diabetes.2 In addition to investigating 
environmental factors, extensive research has also explored immune pathways related to type 1 
diabetes to identify possible immunotherapies.2 Research on the progression of type 1 diabetes 
suggests that an imbalance between T regulatory cells and effector T cells affects the immune 
response and contributes to type 1 diabetes progression.2 Additionally, research involving stem 
cells seeks to develop functional insulin-producing β cells for transplantation, which has been 
explored with diabetic mouse models.8 Ongoing efforts are necessary to identify specific 
pharmacologic targets at the cellular level by isolating the cellular mechanisms that regulate the 
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immune response involved in the development of type 1 diabetes as well as further work with 
stems cells that focus on drug discovery and transplantation.2,8 Although continued research is 
necessary to identify a cure for type 1 diabetes, improving self-care management for the millions 
affected by this disease is also paramount. To improve the lives of those with type 1 diabetes 
through research and clinical care, it is necessary to understand the intensive nature of type 1 
diabetes management and the importance of approaching youth with type 1 diabetes from a 
developmental perspective.  
Diabetes Management 
In diabetes management, the metric that measures the normalization of glucose control 
and is a significant marker to target related to diabetes complications is the HbA1c,1 which is a 
measure of the mean glucose over the past 2-3 months. The HbA1c goal for youth with T1D is 
<7.5% (reference range 4-6%).1 Today, diabetes management includes frequent daily blood 
glucose monitoring and intensive insulin therapy to maintain glycemic control. Research has 
shown that the frequency of glucose monitoring is related to glycemic control; adding one 
glucose check a day can improve the HbA1c by almost 0.5% in patients checking 0-5 times 
daily.1,6 Often, patients with type 1 diabetes conduct blood glucose self-monitoring 6-10 times 
daily to balance food, insulin and exercise as well as to prevent and treat hypo- and 
hyperglycemia.1 In addition to frequent blood glucose checks, patients with type 1 diabetes need 
to administer either multiple daily insulin injections (3 or more) or multiple insulin boluses via 
subcutaneous insulin infusion (insulin pump) to maintain glycemic control. While the DCCT 
demonstrated the importance of intensive insulin therapy, advances in diabetes technologies also 
have proven effective. A more recent randomized controlled trial comparing sensor-augmented 
pump therapy (RT-CGM and insulin pump) with multiple daily injections demonstrated that 
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patients with type 1 diabetes who received sensor-augmented pump therapy had a significant 
improvement in HbA1c at 12 months when compared to the injection-based group.9 Yet, new 
educational and behavioral strategies are needed to help youth with type 1 diabetes implement 
and benefit from advanced diabetes technologies. 
Even with such developments in evidence-based practice and advancements in diabetes 
therapies, management of this disease is challenging. Despite a patient and family’s best efforts 
with diabetes management, blood glucose values often fluctuate leading to intermittent hypo and 
hyperglycemia. Patients and families must be cognizant of the acute complications associated 
with hypo- and hyperglycemia in the short term, and they must be aware of the importance of 
glycemic control over time. Type 1 diabetes is unrelenting and the management required to 
maintain glycemic control and mitigate the risk of long-term complications is meticulous. 
However, children with type 1 diabetes have the full potential to live active healthy lives 
supported by knowledgeable caregivers.  
The multidisciplinary diabetes team is another key component to diabetes management 
success.10 Typically composed of endocrinologists, nurse educators, dieticians, psychologists, 
and child life staff, the team provides developmentally appropriate education to enhance diabetes 
self-management skills. As a child goes through certain developmental stages, the diabetes team 
must direct their education and communication with the child and family from the perspective of 
the child. Developmentally appropriate care is critical because the educational approach and care 
needs of the child and family differ based on a child’s developmental stage.1 This tailored patient 
care is particularly important during the transition to adolescence, which can be a time of unique 
challenges associated with increased adolescent independence with self-care tasks, diabetes-
related family conflict, and risk taking behaviors.1 Specifically, diabetes providers facilitate 
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identifying barriers to self-care and goals to overcome such challenges.1 Adhering to type 1 
diabetes management tasks during childhood and adolescence is demanding and provides 
challenges to both patients and families. Improvements in diabetes therapies can augment the 
demands of diabetes because most technology advances require time and effort on behalf of the 
child and family. For example, insulin pump therapy can provide greater flexibility with insulin 
dosing as well as more fine-tuned improved control.1,6 Yet, pump therapy requires more frequent 
blood glucose monitoring and a heightened awareness of ketone monitoring to avoid diabetic 
ketoacidosis related to failure of an insulin pump/site.6 Thus, the multidisciplinary team must be 
aware of the potential for increased burden given the demands of intensive insulin therapy. The 
team is a pivotal form of support, helping to navigate the complexities of diabetes management, 
particularly with the advent of new technologies.  
Although the DCCT established the necessity of intensive insulin therapy to optimize 
long-term health outcomes, today’s youth continue to struggle with effectively maintaining this 
intensive therapy. Following the DCCT, a cohort of adolescents from the original trial 
participated in a longitudinal observational study entitled The Epidemiology of Diabetes 
Interventions and Complications (EDIC).11 During the first 4 years of the EDIC study, there was 
a small but significant increase in the HbA1c of the adolescents who had been in the intensively 
treated DCCT group. Researchers speculate this deterioration in control was likely due to the 
removal of intensive staff support that the DCCT previously provided.11 The multidisciplinary 
clinical and research team must work to identify ways to effectively implement and sustain type 
1 diabetes self-management during the dynamic process of childhood development. An 
important construct to consider within diabetes management and the changing landscape of 
diabetes therapies is self-efficacy. Self-efficacy research holds the potential to inform and assist 
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the diabetes team as well as patients with type 1 diabetes, particularly as diabetes treatments 
advance. 
Continuous Glucose Monitoring 
A majority of today’s youth with type 1 diabetes do not meet HbA1c targets necessary to 
mitigate the risks associated with diabetes complications.12 In 2014, the American Diabetes 
Association lowered the glycemic or HbA1c target across the pediatric age span, reinforcing the 
need to optimize glycemic control. RT-CGM, can improve glycemic control; however, adhering 
to rigorous type 1 diabetes management and consistent CGM use is a challenge because many 
youth find it difficult to wear CGM for daily self-management.13 CGM entails inserting a sensor 
into the skin, wearing the device continuously, and responding to alarms and glucose data. Given 
these demands, youth may be resistant to this technology. However technological improvements, 
such as thinner sensors/receivers14 and water resistant capabilities,15 as well as use of CGM in 
Artificial Pancreas (AP) research16 support continued efforts to foster use of this technology in 
youth with type 1 diabetes.  
The JDRF landmark RCT evaluated CGM vs. standard of care blood glucose monitoring 
in both youth and adults with the primary outcome being change in HbA1c from baseline to 26 
weeks.17 For the between group analysis, this study demonstrated no significant change in 
HbA1c for youth ages 8-24 years on CGM, while the adult participants (≥25 years) in the CGM 
group showed a significant improvement in HbA1c from baseline to 26 weeks; however the 
youngest participants who were 8-14 years of age and those older than 24 years showed 
improvement in HbA1c when compared to the control group who did not wear CGM. Moreover, 
consistent use (6 days or more) was found in only 30% of participants 15-24 years and in 50% of 
participants 8-14 years compared to 83% of those 25 years or older. This study revealed the 
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benefit of CGM on glycemic control when used consistently as well as the challenge of wearing 
the device consistently. The results also highlight the unique challenges related to CGM use 
during the transition to adolescence. A follow-up study to this RCT investigated the 12-month 
outcomes in this same cohort of youth.13 The results indicated that 21.3% (17/80) of youth were 
consistently using CGM at the 12-month time point, with consistent users having a significantly 
lower HbA1c. A subsequent study evaluated psychosocial correlates to CGM in a cohort of 
youth participating in the JDRF trial.18 Although constant use proves advantageous, CGM may 
be associated with a negative affect regarding blood glucose monitoring as well as more long-
term (trait) characteristics of anxiety.18 CGM has the potential to increase burden given the 
increased time and patient effort required to effectively utilize the technology, as well as the 
potential for physical discomfort and body issues related to wearing the device.19 In the pediatric 
population, adherence to the use of CGM and the integration of CGM data into daily diabetes 
self-management remain difficult despite the benefits to glycemic control.13 
Other research has investigated the safety, accuracy, and effectiveness of a closed-loop 
system or artificial/bionic pancreas involving CGM and pump therapy. This automated system 
delivers insulin as well as glucagon based on algorithms that incorporate CGM data and has the 
potential for less patient burden.20 A recent random-order crossover study was one of the first to 
evaluate the bionic pancreas system in an outpatient free-living environment over several days.20 
Specifically, this study compared the artificial pancreas system to the insulin pump for five days 
in 20 adults and 32 teens with type 1 diabetes, with the primary outcomes of mean blood glucose 
and mean percentage of time with hypoglycemia.20 During the control period, patients wore a 
masked CGM and also had the option of using their own CGM. The results demonstrated 
significantly lower mean blood glucose for both adults and adolescents when using the bionic 
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pancreas vs. the control period with the routine insulin pump. Additionally, adults experienced 
significantly less time with hypoglycemia when using the bionic pancreas. This study 
demonstrated the effectiveness of the artificial pancreas system outside of the controlled hospital 
setting and the related benefits to glycemic control.  Although ongoing research is required to 
fine-tune the artificial pancreas system including a more stable form of glucagon as well as a 
more rapid form of short-acting insulin,20 the initial results are promising. With the future of 
diabetes management technologies on the horizon, evaluating the psychosocial implications is 
necessary to determine barriers and facilitators to the use of these technologies. Addressing such 
barriers at the development and initiation of such therapies will be imperative to the technology 
and patient success.19 
Self-Efficacy 
Self-efficacy is an important concept to consider with the use of CGM technology. This 
concept is especially relevant to explore in youth with type 1 diabetes because self-efficacy can 
augment one’s level of drive and action to perform certain challenging tasks,21 (e.g. CGM use). 
Self-efficacy relates to an individual’s assessment of personal capabilities in a certain situation 
and the belief that carrying out self-directed behaviors will lead to a specified desired 
outcome.22,23 Self-efficacy incorporates the element of personal control in goal setting and 
commitment towards goal completion,24 making the level of perceived self-efficacy an important 
factor. The greater the perceived self-efficacy one has, the more likely the individual is to pursue 
and overcome a challenging task.24 Many factors make up self-efficacy including one’s 
experiences, persuasion by others, and knowledge.25 Knowledge or information affecting self-
efficacy comes from various forms such as observation, enactive attainment or the chance to 
proficiently complete a task, and physical elements such as emotions felt during the performance 
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of a task.26 Thus, self-efficacy is a dynamic concept. Additionally, self-efficacy can be 
transferable. Attainment of self-efficacy in one area often translates to an increased perceived 
ability to accomplish other difficult yet similar tasks.22 This attribute of self-efficacy may prove 
advantageous in the population of youth with type 1 diabetes, given the multitude of daily tasks 
necessary in diabetes management. 
Self-efficacy has been widely studied and utilized as a foundational construct in health 
behavior change theories and interventions.25 This construct is applicable across the spectrum of 
health behavior change because the elements that make up self-efficacy are adaptable and can be 
a target of influence.25 Subsequently, health behavior change interventions can focus on any 
factors influencing self-efficacy to create or bolster change.26 
Studies have explored the relationship of self-efficacy with various variables related to 
youth with type 1 diabetes. Research has demonstrated that higher levels of self-efficacy have 
been associated with higher diabetes self-management adherence,27,28 improved glycemic 
control27 and lower HbA1c,29 and increased blood glucose monitoring (BGM) frequency.30 
Studies also have evaluated self-efficacy pertaining to youth and families using diabetes 
technologies. One cross-sectional study evaluated the relationship between pump therapy and 
self-efficacy in a cohort of female youth with type 1 diabetes and found that the female 
adolescents on insulin pump therapy reported higher self-efficacy than those on multiple daily 
injections.31 Another study assessed self-efficacy related to perceived confidence in diabetes 
management in youth initiating insulin pump therapy32 and found that youth reported higher self-
efficacy 6-months after starting an insulin pump.32 The authors suggest this increase in self-
efficacy 6-months following initiation of pump therapy may be related to families feeling more 
independent in making treatment adjustments.32 Since this was a cross-sectional study, the results 
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can only infer associations and not causality.33 
 Self-efficacy also has proven important when investigating health behaviors in adolescents 
without diabetes. One study in over 400 teens found that higher self-efficacy was associated with 
healthier dietary choices.34 Another study used self-efficacy and Bandura’s social cognitive 
theory (SCT) to develop an intervention related to increasing physical activity in female 
adolescents; the results showed that participants in the intervention group significantly increased 
their number of steps as measured by a pedometer.35 Despite the many studies exploring self-
efficacy and diabetes self-management tasks in youth with type 1 diabetes as well as the 
literature identifying the importance of self-efficacy in general health behavior change, there is 
little research on how self-efficacy relates to the advancements of CGM or whether self-efficacy 
is predictive of CGM use in youth with type 1 diabetes.  
Identification of Gaps in Knowledge 
Masked CGM in Youth with Type 1 Diabetes 
As described above, studies have demonstrated the benefits as well as challenges of RT-
CGM technology in youth with type 1 diabetes. Masked CGM technology uses similar sensor 
technology to RT-CGM but is worn for 3 days and can be used on a periodic basis to identify 
glucose patterns. The data are obtained retrospectively vs. real-time; therefore, the data are 
“masked” during the sensor wear and provide an alternative to RT-CGM. Additionally, masked 
CGM technology has the potential to be less burdensome for the patient because there are no 
alarms to trouble-shoot, and patients do not need to manage glucose data every five minutes. 
Masked CGM provides options for patients who are interested in trying intermittent sensor wear 
prior to obtaining a RT-CGM system or to visualize glucose trends over time not readily 
available from the routine self-blood glucose monitoring checks.  
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Research has confirmed the effectiveness of masked CGM in both pediatric and adult 
patients with diabetes. One prospective cohort study evaluated the use of masked CGM over 
three days related to the ability to detect hypoglycemia in 27 youth with type 1 diabetes.36 The 
results of this six-week study demonstrated the benefit of this technology’s ability to identify 
unrecognized hypoglycemia as well as decreasing future hypoglycemia by making insulin 
adjustments from the CGM data. Another study used the masked CGM device in 56 youth with 
fairly well controlled type 1 diabetes to evaluate glucose patterns.37 The findings showed that the 
masked CGM was useful in identifying substantial post meal hyperglycemia even with pre meal 
glucose values near target and with a mean HbA1c of 7.7 ± 1.4% for the participating youth, 
demonstrating the benefit of masked CGM in conjunction with routine self-blood glucose 
monitoring. Lastly, two other studies conducted a retrospective analysis of adults with type 1 
diabetes or type 2 diabetes who had undergone a three day wear of masked CGM to evaluate the 
impact on HbA1c.38,39 Pepper and colleagues38 did not find a significant difference in the HbA1c 
pre and 3.8 ± 1.6 months post masked CGM wear, while the article by Leinung et al.39 found a 
small decrease in HbA1c (0.18%, p = 0.04) overall with the greatest improvement noted in 
patients starting with a higher HbA1c as well as those with type 2 diabetes. 
While research has demonstrated the clinical utility of masked CGM, few studies have 
described the process of implementing masked CGM in clinic, specific treatment 
recommendations following masked CGM wear, and the effect of masked CGM and treatment 
recommendations on HbA1c in a contemporary cohort of youth with type 1 diabetes. A greater 
understanding of masked CGM implementation and effectiveness in this specific population will 
add to the state of the science regarding diabetes management technologies in this current era. 
The purpose of manuscript 1 of this dissertation was to address this gap related to masked CGM 
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technology in the pediatric population with type 1 diabetes by conducting a study to evaluate the 
masked CGM process, treatment recommendations, and effect on glycemic outcomes in a sample 
of youth with type 1 diabetes. The investigator led this study’s efforts in terms of data collection, 
analysis, interpretation, and the preparation and submission of the findings as a manuscript. 
Additionally, the investigator was a part of the pediatric nursing team that provided sensor 
insertion, education, interpretation, and data review with the family. 
Instruments to Measure Self-Efficacy in Youth with Type 1 Diabetes 
The literature has established the importance of self-efficacy related to health behavior 
changes, including how self-efficacy may correspond with diabetes management in youth with 
type 1 diabetes. While research has established the relevance of this concept, it is necessary for 
the multidisciplinary diabetes team to understand how self-efficacy may affect diabetes self-care. 
To understand this construct to a greater extent, quantifying self-efficacy through questionnaires 
or survey instruments is pertinent. Although various instruments are available to measure self-
efficacy, to the investigator’s knowledge, no integrative review has evaluated current instruments 
that measure self-efficacy related to type 1 diabetes management in youth and their caregivers. 
The purpose of manuscript 2 in this dissertation was to complete an integrative review 
spanning the past decade (2003-2013) to assess and evaluate critically the extant literature on 
instruments to measure self-efficacy in youth with type 1 diabetes and their caregivers. Exploring 
self-efficacy related to caregivers is significant, given the pivotal role parents and families play 
in a child’s diabetes management. By critically evaluating the available instruments, the health-
care team will be able to identify which instruments are reliable and valid and may be 
appropriate to use in the clinical and research settings and with certain populations. Additionally, 
given the advances in diabetes technologies and management over the past several decades, a 
	   14	  
contemporary assessment of self-efficacy instruments will help distinguish how to measure self-
efficacy in the current era, as well as identify gaps that warrant future research. 
Instrument to Measure Self-Efficacy Related to CGM in Youth with Type 1 Diabetes 
As discussed, technology that enhances diabetes management and subsequent glycemic 
control can provide substantial benefit to an individual living with type 1 diabetes. However, 
such advancements can increase patient burden, given the time and effort the technology can add 
to self-care tasks. Therefore, evaluating psychosocial attributes associated with diabetes 
advances, such as CGM, is important to determine the impact on, and ways to improve, CGM 
wear and to identify youth who may have difficulty with successful CGM use. A systematic 
review and meta-analysis identified two studies that assessed quality of life (QOL) as a 
secondary outcome in relation to CGM use.40 Both studies found that QOL scores were higher 
after using CGM.40 Another study that investigated QOL related to CGM consisted of a sample 
from the landmark JDRF CGM trial.18 The study found no differences in the QOL scores 
between youth, parent, or adult participants in the CGM group as compared to those in the 
standard BGM group. Additionally, a recent consensus statement from the International Society 
of Pediatric and Adolescent Diabetes examined the available evidence related to CGM efficacy, 
as well as the advantages and disadvantages of this technology, and provided recommendations 
related to CGM use.41 The authors concluded that CGM did not seem to affect QOL in youth 
negatively.41  
Yet despite the recent research focus on QOL and CGM, few studies have evaluated self-
efficacy as a construct related to CGM adherence. Thus, ongoing research is necessary to 
determine facilitators of CGM use and to promote adherence to this technology. CGM can 
significantly improve glycemic control if used consistently, but has proven challenging in the 
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pediatric type 1 diabetes population. In particular, research is needed to assess how self-efficacy 
relates to CGM use and adherence in youth with type 1 diabetes in the current era of intensive 
insulin therapy and advanced diabetes technologies. Such research may provide insight on 
whether self-efficacy may be a mediator in a youth’s ability to successfully use and integrate 
CGM into daily diabetes self-management. Additionally, evaluating how self-efficacy relates to 
the use of CGM technology may provide insight on areas of focus in diabetes management 
education and future research efforts.  
While it is important to determine the relationship of self-efficacy related to CGM use, 
there are limited instruments that measure self-efficacy related to recent advances in diabetes 
technologies. To the investigator’s knowledge, there are no available instruments that assess the 
concept of self-efficacy in youth with type 1 diabetes and their parents related to CGM use. 
Therefore, the purpose of manuscript 3 of this dissertation was to determine how self-efficacy 
relates to CGM use by measuring self-efficacy in a cohort of youth with type 1 diabetes who are 
initiating CGM therapy using a novel CGM Self-Efficacy (CGM-SE) instrument and to establish 
its psychometric properties. This research was designed to provide a greater understanding of the 
relationship of self-efficacy to CGM use and thus elucidate important characteristics to foster in 
youth who wear CGM. Such findings pertaining to the relationship of self-efficacy and CGM use 
have potential to increase clinician awareness of an important factor related to youth success 
with the technology and, thus, provide an ability to measure this attribute during a clinic or 
research visit.  
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Theoretical Framework 
The Social Cognitive Theory (SCT) 
The guiding theoretical framework for this dissertation is Bandura’s SCT and, 
specifically, Bandura’s model of self-efficacy. The SCT utilizes a model of adaption and change 
instead of a reactive approach to situations.42 This model highlights how individuals proactively 
cope and adapt to environmental stressors by relying on personal cognitive and emotional 
resources.42 The SCT also posits that the environment interacts with personal and behavioral 
factors to affect an individual’s behavior and that the individual can influence this relationship by 
affecting the environment.25 To incorporate all of these various interactions that influence 
behavior, the SCT consists of the following five categories: a) psychological determinants, b) 
observational learning, c) environmental determinants of behavior, d) self-regulation, and e) 
moral disengagement.25 Self-efficacy, a focus of this dissertation, is an integral concept to the 
SCT and incorporates psychological determinants of behavior.25 Bandura highlighted the role of 
self-efficacy in health behavior change and outcomes with a pictorial representation that is 
adapted below in Figure 1.22 
Figure 1. Adapted figure of Bandura’s model of self-efficacy and the influence on behavior 
change.22 
 
The value in utilizing the SCT for behavior change lies in its holistic approach.  The SCT 
identifies the importance of an individual’s knowledge and confidence (or self-efficacy) in 
	   17	  
controlling or changing a behavior, as well as the social and environment facilitators/barriers of 
change.24 While behavior change interventions can target various constructs within the SCT, 
bolstering self-efficacy may enhance one’s coping mechanisms and efforts towards successful 
behavior change.22  
Together, the three manuscripts of this dissertation build upon one another to explore the 
opportunity to improve glycemic control with CGM data, evaluate the measurement of self-
efficacy in youth with type 1 diabetes, and identify a key gap in knowledge that warrants further 
research i.e., how self-efficacy relates to CGM use in youth with type 1 diabetes and their 
families in the current era of intensive diabetes management. The first dissertation manuscript 
focuses on the behavior (CGM use) component of the above model (Figure 1). The second 
manuscript explores efficacy expectations or self-efficacy related to self-management in youth 
with type 1 diabetes.  Lastly, the final manuscript targets both the behavior and efficacy 
expectations by evaluating a novel instrument to measure self-efficacy related to CGM 
technology. Guided by the SCT and Bandura’s model of self-efficacy, this body of work seeks to 
answer the following research question: How does self-efficacy relate to CGM use and 
subsequent glycemic control in a cohort of youth with T1D and their parents after the initiation 
of CGM therapy? 
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Chapter 2: Treatment Recommendations Following 3-Day Masked Continuous Glucose 
Monitoring (CGM) in Youth With Type 1 Diabetes 
Rasbach, L., Atkins, A., Milaszewski, K., Keady, J., Schmidt, L., Volkening, L., Laffel, L. 
Published in the Journal of Diabetes Science and Technology 2014, Vol. 8(3) 494-497 
Background: Glycemic control remains suboptimal in youth with type 1 diabetes. Retrospective 
continuous glucose monitoring (CGM) has demonstrated utility in fine-tuning diabetes 
management by detecting post-prandial hyperglycemia and hypoglycemia. In this study, we 
explored the process of 3-day masked CGM use, subsequent treatment recommendations, and 
impact on hemoglobin A1c (HbA1c) in a clinic-based sample of youth with type 1 diabetes. 
Methods: Over 2 years, 122 youth were referred for masked CGM. Patients/families completed 
a diary of blood glucose levels, insulin doses, food intake, and exercise during CGM use. HbA1c 
was assessed pre- and 2-3 months post-CGM. Treatment recommendations were formulated 
using data from CGM reports and diaries. 
Results: Mean age was 14.3±3.9 years, diabetes duration was 7.5±4.7 years, and HbA1c was 
8.5±1.1% (69±12 mmol/mol); 61% were pump-treated. Patients received an average of 3.1±1.1 
treatment recommendations following review of the CGM report. Most (80%) received 
reinforcement of the importance of pre-prandial bolusing; 37% received a recommendation 
regarding advanced insulin management (use of combination boluses/attend to active insulin). 
Receipt of the latter recommendation was related to HbA1c improvement ≥0.5% (OR: 4.0, 
P<0.001).  
Conclusions: Masked CGM offers opportunities to guide advanced insulin management (by 
injection or pump), which may yield HbA1c improvements in youth with type 1 diabetes 
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Introduction 
 
Glycemic control remains suboptimal in youth with type 1 diabetes.12,43 Modern 
treatment tools, such as continuous glucose monitoring (CGM), can reduce hypoglycemia and 
hemoglobin A1c (HbA1c);17,44 however, youth are often reluctant to use CGM continuously.13 
HbA1c improvement has been associated with real-time CGM (RT-CGM) use ≥6 days/week, a 
challenge for pediatric patients.13 
Masked or retrospective CGM provides an alternative to RT-CGM for patients.38 Studies 
have demonstrated the utility of masked CGM to identify post-prandial hyperglycemia37 and 
hypoglycemia36 in pediatric patients. In this study, we explored the process of masked CGM use, 
subsequent treatment recommendations, and impact on HbA1c in youth with type 1 diabetes. 
Methods 
Over 2 years, we identified young patients with type 1 diabetes referred for masked CGM 
within a pediatric, adolescent, and young adult diabetes clinic. The Institutional Review Board 
granted waivers of informed consent and authorization for use/disclosure of protected health 
information from the electronic medical record. Following clinician referral, pediatric nurses 
implemented masked CGM (Medtronic iPro™) according to manufacturer’s recommendations. 
Numbing cream/spray and/or child life support facilitated device insertion as needed. 
Patients/families received a diabetes diary to record details of daily blood glucose levels, 
insulin doses, food intake, and physical activity during CGM use. (Copies of the diary are 
available from the authors upon request.) The research team determined completeness of diaries 
based on the 3 aspects of management; diet, insulin, and exercise; used to inform clinical 
decision-making. A lack of recorded data was deemed as incomplete and given the score of 1; 
some data but lacking significant detail was described as partial and given the score of 2; 
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comprehensive data recorded for diet, insulin, and exercise was considered complete and given 
the score of 3. Three research team members established inter-rater reliability of this scoring 
method, which was subsequently used to describe the completeness of the diaries. 
Patients/families received training related to completing the diabetes diary, calibrating the CGM 
1 and 2 hours after insertion, synchronizing CGM and meter times, checking blood glucose 
values pre-prandially 4+ times/day, removing sensor after 3 days, and returning CGM and diary 
to the clinic. 
Following device return, staff downloaded CGM data according to manufacturer’s 
guidelines. Download included the number of interstitial glucose values, mean sensor glucose, 
and standard deviation (SD) of sensor glucose values. A nurse practitioner reviewed CGM 
reports for safety to assess unrecognized hypoglycemia or sustained hyperglycemia with 
immediate contact to family when needed. At a subsequent phone or in-person visit, a nurse 
practitioner reviewed reports with the patient/family and made appropriate treatment 
recommendations (Figure 1). Patients/families were sent copies of the CGM reports prior to 
visits that occurred by phone. Treatment data, demographics, and HbA1c (obtained pre- and ~2-3 
months post-CGM use) were extracted from medical records. 
Data Analysis 
Data are reported as mean ± SD (range), median (interquartile range, IQR), and proportions. We 
defined improvement as a decrement in HbA1c ≥0.5%. Analyses, performed using SAS (v9.2; 
SAS Institute Inc., Cary, NC), included paired and unpaired t tests and Chi-square tests; P ≤ .05 
defined significance.  
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Results 
Sample 
Patients referred for masked CGM (N = 122, 53% female) were 14.3 ± 3.9 years old 
(range 7-28) with type 1 diabetes for 7.5±4.7 years (range 1-23). All received intensive therapy: 
61% pump, 39% multiple injections (34% basal-bolus, 5% basal analog with AM NPH). Mean 
baseline HbA1c was 8.5 ± 1.1% (range 5.8-12.6%) (69 ± 12 mmol/mol [range 40-114]). 
Reasons for Masked CGM 
Patients were often referred for multiple reasons. The most common reasons were 
assessment of hyperglycemia (39%) or hypoglycemia (37%), patient/family interest in RT-CGM 
(37%), and insulin dosing adjustments (27%). Other reasons included evaluation of impact of 
food and exercise and follow-up after diabetic ketoacidosis. 
CGM Data 
Most patients successfully wore CGM following a single insertion; 3 required 
reinsertions. Mean number of sensor glucose readings/patient was 894 ± 136 (range 435-1151), 
capturing 1.5–4 days of CGM. Mean sensor glucose was 181 ± 34 mg/dL (range 103-265 
mg/dL), and mean SD of sensor glucose was 75 ± 16 mg/dL (range 34-114 mg/dL).  
Treatment Recommendations  
Almost all patients (n = 116, 95%) received multiple recommendations following CGM, 
5 (4%) received a single recommendation, and one received none. The mean number of 
recommendations/patient was 3.1 ± 1.1 (range 0-6). Most (80%) received the reminder to give 
insulin pre-prandially as reinforcement of standard care. Other common recommendations 
included specific dose adjustments (bolus and/or basal) and review of insulin action (advanced 
boluses/attention to active insulin) (Figure 1).  
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Figure 1. Percentage of patients who received each treatment recommendation following CGM. 
*Those who received the recommendation to use advanced boluses/attend to active insulin were 
4.0 times more likely to improve HbA1c ≥0.5% than those who did not receive this 
recommendation (P < .001). 
Treatment Outcomes 
To assess impact of recommendations following CGM, we compared patients’ HbA1c 
levels a median of 2.6 months (IQR 1.8-4.3) post-CGM. Mean follow-up HbA1c was 8.4 ± 1.1% 
(range 5.9-12.3%) (68 ± 12 mmol/mol, range 41-111); mean HbA1c change was -0.1 ± 0.7% 
(range -1.9-2.1%) (1 ± 8 mmol/mol, range -21-23). 
About a third of patients (n = 39, 32%) improved HbA1c by ≥0.5%. These patients, 
compared to those without improvement, were older (15.5 ± 4.4 vs. 14.0 ± 3.6 years, P = .04), 
had longer diabetes duration (8.7 ± 4.9 vs. 6.9 ± 4.5 years, P = .05), had higher initial HbA1c 
(8.9 ± 1.0 vs. 8.2 ± 1.1%, P < .001), and received more treatment recommendations (3.5 ± 1.1 vs. 
3.0 ± 1.1, P = .01). HbA1c improvement ≥0.5% was associated with the recommendation to use 
advanced boluses/attend to active insulin); receiving this recommendation increased the odds of 
improving HbA1c ≥0.5% by 4-fold (P < .001). Of those who improved, 60% received this 
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recommendation. Over 95% of participants provided complete or partially complete records with 
respect to diet intake, insulin administration, and exercise over the period of masked CGM use 
that offered adequate information to inform interpretation of the CGM data and direct treatment 
recommendations.  
Discussion 
Among intensively treated young patients with type 1 diabetes, 32% improved their 
HbA1c by ≥0.5% following masked CGM use. Specifically, those who improved were 
significantly older, had longer diabetes duration, had higher baseline HbA1c, and received more 
treatment recommendations following CGM than those without improvement (all P ≤ .05). As 
those with higher baseline HbA1cs were more likely to improve, this could represent regression 
to the mean. Additionally, it is important to note that although the majority did not experience an 
improvement in HbA1c, this improvement was significant for older youth in worse glycemic 
control who need lower HbA1c levels. It is possible that more patients could experience HbA1c 
improvement if CGM use were repeated to confirm patterns to inform management decisions. 
Future research is needed to determine the optimal frequency of diagnostic CGM use to improve 
glycemic outcomes. Nonetheless, patients/families who received guidance about insulin action, 
i.e., advanced boluses/attention to active insulin, were 4.0 times (P < .001) more likely to 
improve HbA1c by ≥0.5%. Notably, this recommendation applied to those treated by injections 
or pumps, and insulin treatment modality was not related to HbA1c improvement. 
The study’s aim was to explore use of masked CGM and identify treatment 
recommendations associated with fine-tuning diabetes management and improving glycemic 
control. Our findings suggest that 3-day masked CGM may offer opportunities to improve 
HbA1c in pediatric patients with type 1 diabetes. Additionally, while a need for reinforcement of 
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fundamentals, like pre-meal bolusing, remains, focusing on advanced skills, like complex 
boluses/attention to active insulin, may yield improved glycemic control. This improvement may 
be attributable to an increased awareness of and adherence to the intricacies of the balance 
between insulin delivery and food intake that is essential to diabetes self-management. Review of 
CGM reports with patients/families helps to reinforce insulin kinetics/pharmacodynamics in 
efforts to explain the delayed peak in insulin action for rapid-acting analogs45 and the impact of 
different foods on post-prandial glycemic excursions.46,47 CGM provided opportunities for 
patient self-management and family education around complex areas pertaining to diabetes 
management, particularly insulin action and use of advanced boluses. 
This study also assessed the role of the pediatric team in clinical use of masked CGM, 
similar to its use in adult patients.48 Successful masked CGM requires qualified and trained 
nurses for multiple tasks including: CGM insertion and instruction/training regarding proper 
calibration and completion of the diabetes diary, CGM data downloads, safety assessment of 
CGM reports, and careful reviews of CGM reports alongside the detailed family-completed 
glucose, insulin, diet, and physical activity diary.  
There are caveats to this analysis. We were unable to assess use of complex bolus doses 
(given by pump or prandial insulin separated into 2 doses for those treated by injections) or 
avoidance of insulin stacking. Additionally, this study only included one-time masked CGM use. 
While all patients received a review of the masked CGM data by phone or in-person, we are 
unable to evaluate whether the method of review or diary completeness directly impacted HbA1c 
change, future research can assess such details. Another limitation in our report is that we are 
unable to compare rates of hypoglycemia pre- and post-CGM use. Finally, as this was an 
observational, descriptive study, we were not able to assess if patients implemented the treatment 
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recommendations and the relationship between adherence to treatment recommendations and 
HbA1c. Nonetheless, it is encouraging to see opportunities with CGM to improve HbA1c in 
young patients. Additional research could also explore the mode of masked CGM review to 
determine the optimal approach for relaying the data to the family, especially in the current era of 
telehealth and m-health. The need and timing of repeat masked CGM use and its potential long-
term benefits related to implementation of treatment recommendations require additional study. 
Future studies can also evaluate whether patients are more likely to transition to RT-CGM after 
masked CGM use and whether such patients are more likely to sustain use of RT-CGM. 
Conclusions 
In summary, this study demonstrated that masked CGM offers opportunities to guide 
advanced insulin management (by pump or injection) and may yield HbA1c improvements in 
young people with type 1 diabetes. 
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Chapter 3: An Integrative Review of Self-Efficacy Measurement Instruments in Youth with Type 
1 Diabetes (T1DM) 
Rasbach, L., Jenkins, C., Laffel, L. 
ePublished ahead of print in The Diabetes Educator 12 September 2014 DOI: 
10.1177/0145721714550254 
Purpose: The purpose of this study is to assess the extant literature on instruments used to 
measure self-efficacy in youth with type 1 diabetes and their caregivers and to critically evaluate 
these measurements. 
Methods: An integrative review (2003-2013) was conducted searching PsycINFO, Cumulative 
Index to Nursing and Allied Health Literature (CINAHL), and U.S. National Library of 
Medicine PubMed service (PubMed) databases using key words diabetes, type 1 diabetes, and 
self-efficacy.  The authors reviewed the resulting 294 references for inclusion criteria of (a) 
sample of youth with type 1 diabetes or sample of caregivers of youth with type 1 diabetes, (b) 
description of the self-efficacy instrument as primary research, and (c) the instrument measured 
self-efficacy specifically related to diabetes management. Forty-five articles out of the initial 294 
met criteria.  
Results: Of the 45 articles, 10 different self-efficacy instruments were identified.  The primary 
theoretical framework used was Bandura’s social cognitive theory and model of self-efficacy.  
Most participants were white middle class type 1 diabetes youth.  Evaluations to assess validity 
often were not reported; however, a majority of studies reported high internal consistency of the 
instruments.  
Conclusions: Sample homogeneity could limit the applicability of results to certain patient 
populations.  Further psychometric analysis, including validity assessments, should be conducted 
in more diverse samples. Development of valid and reliable instruments for measuring self-
efficacy that are sensitive to change across a wider caregiver base over time is necessary. While 
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this review examined reliable and valid instruments used in research, future opportunities include 
evaluation of measuring self-efficacy in type 1 diabetes youth exposed to recent advances in 
diabetes management technologies. 
 Adhering to rigorous type 1 diabetes management during the complex stages of normal 
growth and development in childhood and adolescence is a significant challenge that impacts 
both youth with diabetes and their parents/guardians.  Improved intensive therapy options can 
add to these challenges, as currently available therapeutic advances require self-management. 
Despite these improvements and a well-established correlation between adequate glucose control 
and reduced risk of complications, youth with type 1 diabetes often fail to meet the suggested 
hemoglobin A1c (HbA1c) targets necessary to mitigate associated risks.49-52 Enhanced diabetes 
self-efficacy has been linked to improved diabetes self-care and glycemic control and is an 
important indicator of health behavior changes in youth.27,53 Self-efficacy, or one’s perceived 
ability to follow a diabetes treatment program, is important to foster in type 1 diabetes youth and 
their caregivers given the demands of diabetes self-management.54 Therefore, it is important for 
diabetes educators to understand the concept of self-efficacy and what measures are available to 
assess self-efficacy in youth with type 1 diabetes. The purpose of this integrative review was to 
identify measurement instruments to assess self-efficacy in youth with type 1 diabetes and to 
evaluate the reported psychometric properties of those instruments.   
 Theoretical and operational definitions allow for greater understanding and means to 
measure self-efficacy.55 A theoretical definition of self-efficacy includes the belief that an 
individual has the ability to create change by personal actions.24 In type 1 diabetes, operational 
definitions are informed by data from self-report surveys that assess one’s level of confidence or 
self-efficacy to accomplish diabetes management tasks, such as blood glucose monitoring, 
	   29	  
insulin administration, and attention to diet and exercise, in everyday living and in difficult 
situations that may occur.  Self-efficacy is important to capture in youth with type 1 diabetes 
because higher levels of diabetes specific self-efficacy may result in increased resilience when 
youth face barriers or challenges associated with diabetes self-management.27 Therefore, ongoing 
work to measure and optimize self-efficacy in youth with type 1 diabetes is necessary to equip 
youth to manage this disease long-term.  This can be particularly important during transition 
periods across the lifespan of childhood as diabetes management gradually transitions from 
parents to older children and adolescents and then becomes the sole responsibility of college 
aged youth or young adults living on their own. 
Methods 
The literature search focused on (a) identifying instruments used to measure the construct 
of self-efficacy in youth with type 1 diabetes and their parents and (b) evaluating the reported 
psychometric properties of those instruments. For an appropriate literature search, at least two 
different search strategies are necessary according to Whittemore and Knafl’s integrative review 
methodology.56 This literature search used PsycINFO, Cumulative Index to Nursing and Allied 
Health Literature (CINAHL), and U.S. National Library of Medicine PubMed service (PubMed) 
to obtain applicable articles.  Search engines from nursing, psychology, allied health, and 
medical literature provided the opportunity to assess the measurement of self-efficacy across 
disciplines.  Because of the unique attributes of type 1 diabetes disease management in this 
particular population, the search focused on studies of youth with type 1 diabetes.  Additionally, 
the search included articles across all pediatric age groups and their caregivers involved in the 
care and management of type 1 diabetes.  International literature that was translated into English 
was retained because evaluating the concept across geographies could add a valuable cultural 
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perspective. This search included articles measuring specific areas of self-efficacy within 
diabetes management (healthy eating, being active, monitoring, taking medication, problem 
solving, reducing risks, and healthy coping, which are the seven self-care behaviors guiding 
diabetes education).57 To obtain a contemporary perspective on available instruments, only 
primary research published between 2003 and 2013 was included.  
 
Figure 1 presents an overview of the literature search and is a CONSORT flow diagram 
of the search methodology.58 The first database search occurred with PsycINFO. An initial 
search included the terms “diabetes” and “self-efficacy”, and an additional search included the 
terms “type 1 diabetes” and “self-efficacy”. The investigators conducted searches with both 
diabetes and type 1 diabetes to ensure comprehensiveness.  Limits of “English, last 10 years of 
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publication, and childhood age (birth-17 years)” were applied. The age limit for the PsycINFO 
search ended at 17 instead of 18 years because 18 years and older is classified as adulthood in 
this search engine.  The results were evaluated for applicability, availability, and relevance; a 
total of 28 articles met inclusion criteria.  The second database search occurred with CINAHL 
and included combined searches with “diabetes” and “self-efficacy” as well as “type 1 diabetes” 
and “self-efficacy”. After applying the limits of “English, last 10 years of publication, and ages 
birth-18 years”, this search identified 16 articles that met inclusion criteria and were not 
duplicates from the prior search.  A third search occurred in PubMed and included the MeSH 
terms “diabetes mellitus” and “self-efficacy” and then “type 1 diabetes” and “self-efficacy”.  To 
add precision to the search, the authors specified the MeSH term “self-efficacy” as a major term.  
Adding the limits of “English, last 10 years of publication, and ages birth-18 years” yielded one 
additional article that was not a duplicate from prior searches.  The search provided a total of 45 
articles that discussed the use of 10 instruments for measuring self-efficacy in youth with T1DM 
and/or their caregivers.  
Tables 1 to 3 contain matrices of relevant articles categorized by type of self-efficacy 
instrument with particular attention to study sample, instrument characteristics, and instrument 
psychometrics.  The Oxford Centre for Evidence-based Medicine-Levels of Evidence was used 
to evaluate each study based on study design and analysis.59 Two of the investigators (LR and 
CJ) evaluated each study to determine the level of evidence and to establish inter-rater reliability.  
The level of agreement was 100 percent.  
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Results 
Research Process 
The authors summarized the results based on theoretical frameworks for the respective 
articles, sample characteristics, instrument descriptions, scoring, and psychometrics (Tables 1 to 
3).  Table 1 identifies and describes the various instruments and the identified studies, while 
Table 2 includes information about the theoretical framework and sample in each article, and 
Table 3 describes the psychometric details of the measurements and outcomes related to self-
efficacy. 
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Table 1. Instruments Used to Measure Self-Efficacy in T1DM Youth and Caregivers 
Instrument/ 
Reference 







3 subscales: diabetes-specific self-efficacy (24 items), medical situations self-efficacy (5 
items), general situations (6 items) questionnaire assessing perceived self-efficacy to manage 
T1DM60; Likert-like response categories 1-5 with “1 = very sure I cannot” to “5 = very sure I 
can”61,63,67,70,73-75 or “1 = very sure I can” to “5 = very sure I can’t”65 or a 6-point Likert-like 
scale31,62,64,72 or a 5-point Likert scale with 0-4 “0 = very sure I can” to “4 = very sure I 
cannot”.69 Some studies report 12-item70 or 33-item72 instrument. 
Scoring:   
Scoring differed by study(ies). 
Total scores represented by mean item score.61 Higher scores reflect greater self-
efficacy31,67,72-75 or more confidence.70  
Modified to include current 
aspects of T1DM (pump 
therapy).71 
SED adapted for parent use 
with 22-items and youth 
parent dyads completed the 
survey.67,73 
SED adapted for parent use 
only with 19-items.54,74,75 








10 item questionnaire assessing perceived self-efficacy to perform diabetes care behaviors 
with Likert-like response categories 1-10 with “1 = not at all sure” to “10 = completely sure”. 
One study used a scale ranging 1-5.30 
Scoring: 
Instrument adapted for use in 
youth-parent dyads (either 
mother, father, or 
both).53,78,80,81  
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Table 1. Instruments Used to Measure Self-Efficacy in T1DM Youth and Caregivers 
30,53,76-82 
 
Scoring differed by study(ies)  
Higher scores indicating higher levels of self-efficacy.28,30,53,81,82 Youth and parent scores 






28 items composed of 3-subscales rating diabetes specific self-efficacy in managing 
psychosocial aspects of diabetes, assessing dissatisfaction, and readiness to change and setting 
and achieving diabetes goals, using 5-point Likert-like scale ranging from 1 = strongly agree 
to 5 = strongly disagree.83  
Scoring:  
Mean scores provided in each study.54,83  
One study used the DES in 







7 items indicating confidence about ability; for each item, numbers converted to A+ = 100 
“could not do better” to F = 20 “you are a disaster” using scale 20-100.87 8 item questionnaire 
assessing perceived related to diet, glucose monitoring, insulin administration, exercise, and 
hypoglycemia behaviors with grading A+ = 9 could not do better” to F = 1 “you are a 
disaster”85; Participant graded themselves on tasks with grade ranging from A+ to F with total 
score ranging 8-72.84,86  
Two studies used modified 
instrument adding item related 
to hypoglycemia to make total 
of 8-items.84-86 
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Table 1. Instruments Used to Measure Self-Efficacy in T1DM Youth and Caregivers 
Scoring:   
Scoring differed by study. 
A+ was equal to a score of 9 and F equal to a score of 1 for each item with the total score 
being the sum.85 






9 items rating confidence about following dietary plan related to barriers of temptations, 
negative mood, and uncontrollable situations; 10-point scale ranging from 0 = not confident 
in following dietary plan to 10 = confident in following dietary plan88; adapted scale to 
measure confidence in dietary self-care activities with 26 items/common barriers, using 11-
point Likert scale of 0 = not at all confident to 10 = totally confident.89,90 
Scoring:   
Higher scores indicate more self-efficacy 
Adapted to use with 






8 item questionnaire assessing beliefs about personal exercise capability, Likert-like response 
categories with “1 = not at all true” to “5 = very true”.91 
Scoring:   
Survey assisted in 
development of exercise 
program and examined 
changes post intervention.91 
	   36	  
Table 1. Instruments Used to Measure Self-Efficacy in T1DM Youth and Caregivers 




8 item questionnaire measuring level of self-confidence performing diabetes care-related 
tasks, 10-point semantic differential scale with “1 = not at all confident” to “10 = totally 
confident”.92 
Scoring: 







8 item questionnaire measuring confidence in managing glycemic control well, 5-point 
Likert-like scale with “1 = strongly disagree” to “5 = strongly agree”.93 
Scoring:  
Four items reverse-scored, scores ranged 8-40 with higher scores indicating greater 
confidence.93 







17 item questionnaire to assess maternal self-efficacy in areas of illness, exercise, response to 
high or lower blood glucose, adjusting insulin doses, and acting as child’s advocate, 5-point 
Likert scale with “1 = not at all confident” to “5 = very confident without help”.94 
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11 item questionnaire measuring self-efficacy about specific factors related to performing 
diabetes care and education in school setting, 5-point Likert scale with “1 = not at all 
confident” to “5 = completely confident”, stem “ I feel confidence with diabetes education 
when…”23 
Scoring:  
Determined by adding responses of all questions, highest score 55 indicates complete 
confidence, score 44 high confidence, score 33 moderate confidence, 22 low confidence, 
lowest score 11 no confidence23 
  
NOTE:  A table summarizing each study is available from the author. 
£One study82 used the Diabetes Management Self-Efficacy Scale (DMSES) by Iannotti et al. (2004) from paper presented at the Society of 
Pediatric Psychology National Conference on Child Health Psychology.   
Legend for abbreviations: Type 1 Diabetes (T1DM), Self-Efficacy for Diabetes Scale (SED), Self-Efficacy for Diabetes Self-Management 
(SEDM), Diabetes Empowerment Scale (DES) 
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Table 2: Theoretical Framework and Sample Used in Articles Measuring Self-Efficacy 
Instrument/ 
Reference 






Self-efficacy theory54; Self-efficacy: Not stated but 
implied31,72; Stress adaptation model60,65,71; Social 
ecological model61; Bruhn and Parcel model of  
health promotion63; Social cognitive theory65; 
Biopsychosocial model66; Johnson’s biobehavioral 
model75; Transtheoretical model67; Self-regulation 
theory70; Not identified32,62,64,68,69,73,74 
Sample size: n = 1454 to 51569 
Subjects largely white or white and upper/middle income31,60-63,65-67,69-75 
Age range across studies: 3.9-21 years old*31,32,60-73 
Parents of youth with T1DM54,60,62,65-68,73-75 







Self efficacy: Not stated but implied77,80,81; Bandura’s 
Social Cognitive Theory27; Dyadic models of 
coping79; Risk and Resistance model of chronic 
illness adaptation82; Family organization53; Not 
identified28-30,76,78 
Sample size: n = 13729 to 76628 
Subjects largely white and/or upper/middle income27,29,30,53,76-82 
Age range across studies: 2-18 years old* 




Extended health belief model83; Self-efficacy theory54 Sample size: n = 1454 to 11883 
Age range: 16-25 years old83 
Parents of youth with T1DM54 
Diabetes- Social cognitive perspective-self-efficacy86; Self- Sample size: n = 5687 to 20486 
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efficacy87; Not identified84,85 Subjects were largely white or white and upper/middle income84-86 





Self-Determination Theory88; Leventhal, Meyer, and 
Nerenz’s self-regulatory model of illness 
representations89,90; Social-cognitive theory/self-
efficacy90 
Sample size: n = 15190-28988 
Age range across studies: 11-18 years old88-90 






Personalized exercise prescription intervention 
model91 
Sample size: n = 1291 
9 subjects non-Hispanic white, 3 subjects Hispanic; no SES data91 
Age range: 12-19 years old91 
Parents of youth with T1DM91 
Diabetes self-
efficacy scale92 
Not identified92 Sample size: n = 12392 




Not identified93 Sample size: n = 5293 
Age range: 12-20 years old93 
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Self-efficacy94 Sample size: n = 4194 





Bandura’s Theory of Self-Efficacy23 Sample size: n = 11523 
School nurses at elementary and middle schools in suburban New 
England23 
*Youth as young as 8 years old completing surveys may alter results for adolescents60,65; youth as young as 8 years old interviewed for scale 
development27; study recruited families of youth with T1DM between ages of 2 and 17 years old; however, only adolescents ages 12 to 17 years 
old completed SEDM28 
Legend for abbreviations: Type 1 Diabetes (T1DM), Self-Efficacy for Diabetes Scale (SED), Self-Efficacy for Diabetes Self-Management 
(SEDM), Diabetes Empowerment Scale (DES) 
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Reliability of Instrument Outcomes related to Self-








	  Confirmatory factor 
analysis66; Used to 
establish construct 











Cronbach’s α = .88 to 
.9463,64,70; diabetes 
subscale .84 to .9060,64,71; 
medical subscale .6064 
and .7160; general 
subscale .5864 and .7060; 
α = .8465 and .8769 for 
diabetes subscale only, 
.87 to .88 for parents 
only,74,75 .88 to 
.90,61,62,64; .90 for youth 
and parents67,73; 
reliability coefficient 
=.90 to .92 (unclear if  
established in this study 
or previous studies)68; 
not reported31,32,54,66,72 
 
Outcomes: Higher self-efficacy for 
female teens on pump therapy 
compared to multiple daily 
injections31; more parental 
emotional support and maternal 
acceptance associated with higher 
self-efficacy62,63; better diabetes 
problem solving related to higher 
self-efficacy and youth self-
efficacy predicted youth 
responsibility for more diabetes 
management66; higher self-efficacy 
reported six months after starting 
pump therapy32; higher maternal 
self-efficacy associated with lower 
rates of health-care utilization by 
youth73; positive relationship 
between social support and self-
efficacy in parents of T1DM youth, 
greater self-efficacy found 
following web-based intervention 
to improve social support in parents 
of T1DM youth.54 
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Table 3. Assessment of Instruments Used to Measure Self-Efficacy in T1DM Youth and Caregivers 
 
Critical parenting associated in 
lower self-efficacy in preteens, 
mediated by depressive 
symptoms61; lower self-efficacy 
mediated relationship between 
depressive symptoms and fewer 
self-care behaviors61; adolescents 
describing mothers as having firm 
control had worse self-efficacy62; 
parents reporting lower self-
efficacy also reported more 
frequent pediatric parenting 
stress.75 
 



















Cronbach’s α = .9027; α = 
.81 to .90,29,76,77,79-82  .87 
Outcomes: Higher self-efficacy 
associated with diabetes self-
management adherence,27,28 good 
glycemic control,27 more 
collaboration between youth and 
primary caregivers,82 patient 
	   43	  









SEDM used as 
convergent 














to .88 for mothers and 
.90 to .91 for fathers,80,81 
.85 for youth and 
parents,53 .88 at baseline 
and .90 at 6 month for 
youth and .90 at baseline 




centered communication with their 
provider,78 blood glucose 
monitoring frequency,30 lower 
HbA1c and higher self-control.29 
 
Higher perceived coping 
effectiveness associated with self-
efficacy across age79 Self-efficacy 
is mediator for association between 
parental-teen relationship and 
diabetes management.77 Higher 
levels of family conflict associated 
with lower diabetes self efficacy.30  
 




None reported 54,83 Test-retest reliability: 
.7983 
Outcomes: High levels of self-
efficacy predicted the benefits of 
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Cronbach’s α = .87, .68, 
.91 for respective 
subscales (psychosocial 




diabetes goals)83; None 
reported54 
adhering to self-care regimen83; no 
significant difference in parent 
DES scores after receiving a web-
based intervention to improve 
social support.54 
 








None reported84-87 Internal consistency: 
Cronbach’s α = .85,84-86 
.8687 
 
Outcomes: For youth living 
independently higher self-efficacy 
associated with greater 
responsibility84; diabetes 
management better for youth with 
higher self-efficacy.85 Lower self-
efficacy associated with greater 
responsibility for adolescents living 
at home after high school.84 
 
Level of Evidence: 
2b84-87 
Dietary Self- None reported88-90  Internal consistency: Outcomes: Dietary self-care 
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Cronbach’s α =.86,88 
.95,89,90 .98 for parents89 
 
positively and significantly related 
to self-efficacy88; higher levels of 
dietary self-efficacy associated 
with less perceived consequences 
of diabetes and diabetes distress but 
stronger beliefs about the effects of 
dietary self-care to control 
symptoms and greater dietary self-
care.90 Adolescent diabetes distress 
related to lower self-efficacy and 
dietary self-efficacy predicted 
adolescent diabetes distress.89	   
 








None reported91 None reported91 Outcomes: Perceptual factors 
influencing adherence to exercise 
was not strongly associated with 
exercise self-efficacy.91 
 




None reported92 Internal consistency: α = 
.7792 
Outcomes: No difference in self-
efficacy between rural/urban youth; 
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Table 3. Assessment of Instruments Used to Measure Self-Efficacy in T1DM Youth and Caregivers 
higher diabetes self-efficacy, lower 
risk behavior, predicted better 
diabetes self-care, which 
subsequently predicted better 
glycemic control and mental 
health.92 
 






None reported93 Internal consistency: α = 
.8093 
Outcomes: Higher self-efficacy 
related to good metabolic control 
and patients more likely to reach 
target diabetes control.93 Lower 
self-efficacy found in youth who 
had longer diabetes duration.93 







established from 2 
parents of youth with 
diabetes and 3 nurse 
practitioners94 
Test-retest reliability: 
coefficient of stability = 
.7594 
Outcomes: Maternal coping 
resources significantly related to 
maternal diabetes self-efficacy.94 
No significant relationship between 
maternal self-efficacy and maternal 
diabetes management behaviors.94 
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Table 3. Assessment of Instruments Used to Measure Self-Efficacy in T1DM Youth and Caregivers 





Sent to 5 school 
nurse experts for 
content23 
Internal consistency: α = 
.9423 
Outcomes: Significant relationship 
between greater self-efficacy and 
having a diabetes curriculum; 
significant positive relationships 
between self-efficacy and 
participating in care of children 
with diabetes, having T1DM youth 
in the school system, and 
supervising blood glucose 
monitoring.23 
Level of Evidence: 
2b23 
Legend for abbreviations: Type 1 Diabetes (T1DM), Self-Efficacy for Diabetes Scale (SED), Cognitive 
Behavioral Therapy (CBT), Self-Efficacy for Diabetes Self-Management (SEDM), Diabetes 
Empowerment Scale (DES) 
Legend for Levels of Evidence: 1a systematic review (SR) of randomized controlled trials 
(RCT)/inception cohort studies/diagnostic studies/prospective cohort studies/economic studies; 1b 
individual RCT, individual inception cohort study with >80% follow-up, validating cohort study, 
prospective cohort study with good follow-up; 1c all or none case series; 2a SR of cohort 
studies/retrospective cohort studies or untreated control groups in RCTs; 2b individual cohort study 
(including low quality RCT), retrospective cohort study, exploratory cohort study; 2c outcomes 
research/ecological studies; 3a SR of case-controlled studies; 3b individual case-control study, non-
consecutive cohort study; 4 case-series; 5 expert opinion without critical appraisal.59  
 
Theoretical frameworks 
Theory driven measurement assigns meaning to a research question, clarifies associations 
between concepts, and gives researchers a guide to explore a specific concept.55,95 A lack of a 
theoretical framework in instrument development jeopardizes the ability to adequately measure a 
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concept. Despite the importance of a theoretical framework, many of the articles analyzed in this 
integrative review did not identify a theoretical framework, as indicated in Table 2, column 2.   
Of the 28 articles evaluating youth or caregiver self-efficacy that identified or implied a 
theory, the most common framework was Bandura’s social cognitive theory (SCT) or model of 
self-efficacy.23,27,54,65,86,87,90,94 Although not explicitly stated, an additional five studies implied 
Bandura’s model of self-efficacy.31,72,77,80,81  
Less common, yet applicable, frameworks included the extended Health Belief Model 
(HBM),83 the risk and resistance model of chronic illness adaptation,82 and the stress-adaptation 
model.60,65,71 Each of these guiding models related to the construct of self-efficacy or 
patient/family adaptation to chronic disease management. 
Sample and subjects 
 Since the purpose of this integrative review was to identify self-efficacy measures in 
youth with T1DM and their caregivers, all identified studies included a sample of children or 
adolescents or parents/caregivers.  Many studies had youth ≥10 years old complete the various 
instruments; yet, a few had participants as young as 8 years old.60,65 Of the 45 articles in the 
review, 39 encompassed an adolescent age range of participants27-32,53,60-73,76-93 (10-18 years old 
as defined by the American Psychological Association),96 25 studies included parents as 
participants,27-30,53,54,60,62,65-68,73-82,89,91,94 and 11 studies measured parental self-efficacy in 
diabetes management53,54,67,73-75,94 or parental confidence in their child.78,80,81,89 One study 
measuring self-efficacy in diabetes care and education focused on the role of school nurses in 
diabetes management (including both type 1 diabetes and type 2 diabetes),23 and one focused on 
the role of camp counselors.70 
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 An analysis of participant demographics revealed that 31 studies had a homogenous 
sample that included white and/or middle-class participants.27,29-31,53,60-63,65-67,69-82,84-86,91,94 
Additionally, 10 studies took place internationally, outside of the United States.28,32,64,83,87-90,92,93 
Evaluation of Instruments 
This integrative review identified 10 instruments to measure self-efficacy in youth with 
T1DM and their caregivers.  Given the inclusion criteria of articles from the last decade (2003-
2013), the initial literature search did not reveal the original articles that described all of the 
instruments. The following instruments were identified: a) Self-Efficacy for Diabetes scale 
(SED); b) Self-Efficacy for Diabetes Self-Management scale (SEDM); c) Diabetes 
Empowerment Scale (DES); d) Diabetes-Specific Self-Efficacy Scale; e) Dietary Self-Efficacy 
Scale; f) Perceived Self-Efficacy Scale related to exercise; g) Diabetes Self-Efficacy Scale; h) 
Perceived Diabetes Self-Management Scale (PDSMS); i) Maternal Self-Efficacy for Diabetes 
Management Scale; j) Self-Efficacy in Diabetes Education (SEDE).    Of the 10 instruments, four 
were used in youth,84-87,91-93 three were used in youth/parents,27-30,53,54,76-83,88-90 one was used in 
youth/parents/camp counselors,31,32,54,60-75 one was used in mothers,94 and one was used in school 
nurses.23 The most commonly used instruments were the original and adapted SED31,32,54,60-75	  and 
the original and adapted SEDM.27-30,53,76-82 One study used two instruments, the SED and the 
DES, to measure parental self-efficacy.54   
Instrument description 
 All instruments used either a Likert-like scale or a semantic differential scale,97 except 
the Diabetes-Specific Self-Efficacy Scale, which used scoring from 20 (F) to 100 (A+) to 
evaluate perceived self-efficacy.  The instruments ranged from 7 to 35 items with two of the 
surveys (SED and DES) consisting of three different subscales within the self-efficacy 
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measurement.  The SED included subscales for diabetes, medical, and general situations. The 
three DES subscales included managing psychosocial aspects of diabetes, assessing 
dissatisfaction, and readiness to change/goal setting. While all questionnaires assessed perceived 
self-efficacy related to confidence in diabetes management, one instrument explicitly measured 
dietary self-efficacy,88-90 another measured exercise self-efficacy,91 and one assessed confidence 
in diabetes education,23  Surprisingly, only one study described modifying an instrument (SED) 
to incorporate pump therapy.71 The literature search did not identify other measures that assessed 
youth self-efficacy related to current technologies, e.g. pump therapy or continuous glucose 
monitoring.   
Measurement of perceptions and scoring 
 The instruments’ response categories ranged from five- to eleven-point Likert-like scales 
and varied as to whether low or high scores indicated less or greater self-efficacy. All articles 
discussed how scoring related to the level of self-efficacy and/or provided the mean participant 
scores with the respective instruments.  One study using the SEDM survey combined youth and 
parent scores to evaluate family self-efficacy,53 although this combination in scoring differed 
from the original description of the instrument.27 
Method of administration 
 The method and site for instrument completion varied, ranging from the clinical or camp 
setting to completion by mail, the web, or telephone; some studies utilized more than one 
approach. The majority of studies had participants complete the instruments at the time of a 
medical or study visit.30,31,53,60,64-69,73,75-79,81,82,87,88,92,93 The second most frequent method of 
administration was via the mail23,27,29,54,62,74,80,83,90 followed by the web.28,71,84-86 
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Reliability 
 Most articles reported reliability statistics for the self-efficacy instrument under study. 
Although certain studies may not have explicitly stated reliability or validity data, the 
psychometrics from the original studies prior to 2003 were identified; however, caution is 
warranted when applying these psychometrics to different samples. Most studies using the SED 
or an adapted version of the scale reported internal consistency for the diabetes specific 
subscale65,69,71 or total scale61-64,67,68,70,73-75 with α values ranging from .84-.94, indicating a high 
internal consistency. Cronbach’s α values of .70 and greater are considered acceptable.98 Other 
studies using all 3 subscales of the SED reported α values of .84 and .90 for the diabetes 
subscale, .60 and .71 for the medical subscale, and .58 and .70 for the general subscale.60,64 The 
original article by Grossman and colleagues cited a Kuder-Richardson coefficient α of .90 for the 
total scale, .92 for the diabetes subscale, as well as significant intercorrelations among the scales 
in a study sample of 68 adolescents with type 1 diabetes.99  
 Studies using the SEDM scale revealed high alpha coefficients ranging from .81-
.93.27,29,53,76-82 Adapted versions of the SEDM used in parents as well as youth performed well, 
with high levels of internal consistency for parents (α = .85 - .93)53,78,80,81 and slightly lower 
levels for youth (α = .81 -.90).53,78,80,81 The DES demonstrated internal consistency across the 
three subscales of psychosocial aspects (α = .87), dissatisfaction (α = .68), and readiness to 
change/goal setting (α = .91),83 which were slightly lower than the original assessments of the 
total scale (α = .96) and subscales of psychosocial aspects (α = .93), dissatisfaction (α = .81), 
and achieving goals (α = .91).100 The Diabetes Specific Self-Efficacy Scale reported Cronbach’s 
α of .8584-86 and .86,87 which was higher than the originally reported .78.101 The Dietary Self-
Efficacy Scale also reported high internal consistency with Cronbach’s α of .8688 and 0.9589,90 
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for youth and .98 for parents,89 while the original Dietary Self-Efficacy Scale reported a 
Cronbach’s α of .94.102 All but one of the studies representing the remaining five self-efficacy 
scales reported reliability information for the current study participants. The study using the 
Perceived Self-Efficacy Scale related to exercise reported reliability coefficients from past 
studies only.91 The internal consistencies for the Diabetes Self-Efficacy Scale, the PDSMS, and 
the SEDE survey ranged from α = .77-.94.23,92,93 The original PDSMS reported a relatively high 
internal consistency with a Cronbach’s α of .83 in a sample of adults with type 1 diabetes or type 
2 diabetes.103 Similarly, the original report of Diabetes Self-Efficacy Scale had an α of .85 in a 
sample of adults with type 2 diabetes.104 
Test-retest reliability was reported for the Maternal Self-Efficacy for Diabetes 
Management Scale, with a 37% response rate in repeating the measure after two weeks and a 
modest correlation of .75,94 and was reported for the DES with test-retest reliability of .7983. In 
the original study, researchers expanded the SEDM psychometrics by establishing test-retest 
reliability27; they administered the survey twice in 1 week to 38 youth, revealing a test-retest 
intra-class correlation coefficient of .89, reflecting the stability of the scale over time.105 The 
original Perceived Self-Efficacy related to exercise scale also reported reliability using the test-
retest method with a result of 0.989106 and the original Diabetes Self-Efficacy Scale reported a 
test-retest of .80.104 
Validity 
 A few of the articles reported content and face validity of the self-efficacy instruments. 
Content validity was established by consulting school nurses as experts for the SEDE 
instrument23 and parents of youth with diabetes plus nurse practitioners for the Maternal Self-
Efficacy for Diabetes Management Scale.94,107 Similarly, nine family interviews and consultation 
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with experts in developmental psychology and pediatric endocrinology established face validity 
for the original SEDM scale.27 
Factor analysis was another approach to establish validity. In one article using the SED, 
the researchers performed a confirmatory factor analysis among variables that included self-
efficacy to determine the strength of relationships among the variables.66 In the original 
publication of SEDM scale, the authors reported extensive validity metrics, including factor 
analysis and predictive validity.27 They identified significant although modest correlations 
between the SEDM scale and glycemic control (r = .21) and the youth (r = .37) and parent (r = 
.29) report on the Diabetes Self Management survey.27 The original article describing the DES 
reported a single factor for the measure.101   
Other articles described construct, convergent, and concurrent validity. One study used 
the SED to establish construct validity for the survey measuring diabetes self-management, the 
Self-Management of T1DM in Adolescents.69 Although not directly related to the validity of the 
SEDM scale, one study used this instrument to establish convergent validity for another measure, 
Perceived Coping Effectiveness (PCE),79 and another study used the SEDM survey to establish 
concurrent validity with an Adherence in Diabetes Questionnaire.28  
To identify other validity assessments, one must evaluate the original articles describing 
the self-efficacy instruments. The initial article using the SED reported evidence for criterion and 
construct validity for this measure99 while the original DES article reported evidence for 
concurrent validity.100 The original article describing the PDSMS also reported sufficient 
establishment of construct validity.103 Pender and colleagues reported predictive validity, which 
was established with significant correlations with other variables for the Perceived Self-Efficacy 
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Scale related to exercise.106 The original Dietary Self-Efficacy article did not describe a validity 
assessment.102 
Feasibility of instrument use 
 The identified studies did not readily discuss the feasibility of implementation of the 
instruments.55 In some cases, authors identified compensation amounts for study participation or 
the time required for completion; however, the time reported often involved completion of 
multiple questionnaires, not just the self-efficacy instrument.  Therefore, it is difficult to 
ascertain how long each measure takes to complete.  However, Table 1 lists the number of items 
per survey.  Access to the instrument is another feasibility consideration.  On an initial search, 
the majority of surveys does not seem readily available within the public domain and often 
require identifying the original article describing the instrument.  The following instruments are 
publicly accessible: the DES is accessible on the Michigan Diabetes Research and Training 
Center website,108 the Perceived Self-Efficacy Scale related to exercise91 and the Diabetes Self-
Efficacy Scale92 are available through websites noted in the studies’ reference lists. The SEDM 
and PDSMS items are listed as tables in the original studies.27,103 Additionally, the original 
studies describing the Maternal Self-Efficacy for Diabetes Management Scale and the SED 




Despite the importance of theory driven research, not all articles in this integrative review 
on self-efficacy identified a theoretical framework.  Instruments based upon a theoretical 
framework and theoretical definition of the concept of interest will ultimately provide a better 
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means to operationalize the concept.55 Not surprisingly, most studies that did recognize a guiding 
framework used Bandura’s SCT or the model of self-efficacy.  The six constructs of the SCT 
provide a framework for health promotion and chronic disease management to translate health 
knowledge into positive health outcomes.24 These health behavior constructs include the 
following: knowledge, perceived self-efficacy, outcome expectations, goals, perceived 
facilitators, and impediments.24 Knowledge and personal motivation will help individuals face 
challenging situations, which is particularly important in the self-management of chronic 
disease.24 Moreover, the SCT highlights how individuals proactively cope and adapt to 
environmental stressors by relying on personal cognitive and emotional resources.42 The SCT is 
a natural framework to explore the concept and measurement of self-efficacy as well as one’s 
perceived ability to face challenging situations,22 especially in youth managing the rigors of type 
1 diabetes while navigating the developmental stages of pediatric growth and development. 
Additionally, self-efficacy, a central component to the SCT, relates to an individual’s assessment 
of personal capabilities in a certain situation and the belief that carrying out behaviors will lead 
to a specific outcome.22,23 Utilizing the SCT or the model of self-efficacy as the underlying 
framework for development of self-efficacy instruments provides a theoretical overview of how 
youth with type 1 diabetes or their caregivers may carry out specific behaviors related to diabetes 
management in various scenarios.    
 Researchers should also consider the Social Ecological Model (SEM) when measuring 
self-efficacy in youth with type 1 diabetes, as one study identified through this review did.61 
Similar to SCT, the SEM has been used to guide health promotion and may provide a unique 
perspective to assess the multifactorial relationships involved in the concept of self-efficacy for 
youth with type 1 diabetes.109 This widely used framework highlights the potential for dynamic 
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interactions between the individual’s environment and layers of social support. Furthermore, this 
model would have direct application to evaluating various levels of caregiver self-efficacy 
particularly as it relates to the youth with type 1 diabetes. 
Methodological Issues 
 The prevalence of type 1 diabetes in older children is highest in non-Hispanic white 
youth,110 as reflected in the homogenous participant pool of predominately white youth in the 
studies reviewed above.  Thus, the results of this integrative review may not be generalizable to 
non-white youth with type 1 diabetes.  Future research should include purposeful sampling of 
minority youth with type 1 diabetes. Additionally, the majority of participants across the 
reviewed studies were from higher socioeconomic status (SES) backgrounds.  This further limits 
the generalizability of the current assessments of self-efficacy instruments, because youth and 
families from lower SES backgrounds may inherently face more challenges related to financial 
stressors, additionally impacting self-efficacy.  Identifying and testing appropriate measurement 
instruments to evaluate self-efficacy in these vulnerable populations may be increasingly 
important to provide greater understanding of the relevance of this concept in all youth with type 
1 diabetes. 
This integrative review identified self-efficacy instruments at the individual, parent, camp 
counselor, and school nurse level.  The SED, SEDM, DES, Dietary Self-Efficacy scale, the 
Maternal Self-Efficacy for Diabetes scale, and the SEDE, all measure an aspect of caregiver self-
efficacy. Instrument selection depends on the specific participant sample and focus. Capturing 
caregiver self-efficacy is valuable as both family and caregivers outside of the family are an 
integral part of a youth’s success with diabetes management. Additionally, researchers and 
clinicians will be able to fine-tune education efforts by identifying gaps in confidence related to 
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aspects of diabetes management for those involved in the care of the child. However, no articles 
evaluated peer self-efficacy or the perceived confidence of helping a friend manage diabetes in 
challenging situations.  Because support typically shifts from the family system to friends and 
peers in adolescence,111 it would be useful to evaluate peer self-efficacy in diabetes management 
to further guide adolescents through this developmental transition.  Furthermore, youth with type 
1 diabetes often have multiple caregivers beyond the parents or school nurse.  Use of self-
efficacy instruments to assess confidence levels in type 1 diabetes management for grandparents, 
babysitters, and athletic coaches, among others, may expand the self-efficacy knowledge base 
and identify essential educational needs of these important caregivers and other key support 
groups in the community. 
Instruments 
Methods of administration, feasibility, and psychometrics 
There were no major issues identified in administering the 10 instruments to youth or 
their caregivers, since the majority of surveys were administered during an office visit or by 
mail.  One might not expect different psychometric properties according to response mode but 
future research could clarify this issue.  Although none of the studies noted the exact time 
required to complete the respective self-efficacy assessments, time-to-completion did not appear 
to be a burden for survey administration.  One must also consider that all instruments, except for 
three, were administered in English,28,87,93 an important consideration when establishing 
eligibility criteria.  Survey translation would help broaden international access and 
generalizability.  The main feasibility issue in fielding the various surveys is access to the 
instruments. The research team should consider the need to search for and possibly purchase 
surveys when developing a study budget.   
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Most instruments measuring self-efficacy demonstrated internal consistency, a form of 
equivalence reliability, indicating the items within the instrument conceptually fit with one 
another.105 However, it is important to consider that the internal consistency may vary based on 
the number of response options used in the Likert scale with a higher number of responses 
resulting in greater internal consistency112 and that the alpha value may also vary based on the 
number of survey items.98 Both the number of Likert options and survey length varied based on 
the different instruments. Apart from the SED and SEDM, extensive validity assessments for the 
different instruments were not frequently described. Often, the authors had to revert back to the 
original article describing the psychometrics of the self-efficacy instrument to obtain validity 
evidence. Even in these cases, the original sample may have included adults with type 1 diabetes 
or type 2 diabetes vs. youth with type 1 diabetes. The lack of validity data reported in the 
identified articles is a limitation of the contemporary literature. Validity assessments are 
paramount to evaluating an instrument’s capacity to measure self-efficacy or the concept of 
interest within a certain population.105 During instrument development and refinement, when 
translating available instruments into different languages, or when using instruments in different 
patient samples, validity tests reinforce the adequate measurement of self-efficacy. Additional 
research efforts should establish further psychometric analysis of these instruments in diverse 
populations of youth with type 1 diabetes because the sample homogeneity from the identified 
articles could limit the applicability of the results.   
When evaluating the various self-efficacy instruments identified, it is important to 
acknowledge that many of the self-efficacy instruments were used in multiple articles 
highlighting the affinity for use. The SED and SEDM were the self-efficacy instruments most 
often used in the identified articles. Additionally, several studies from this integrative review 
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revised or adapted the self-efficacy instrument to include a certain population, such as youth 
parent dyads for example, which clinicians and researchers should consider when selecting an 
instrument based on a specific population.  
Another element to consider when evaluating self-efficacy instruments for future research 
and clinical care pertains to the ability to measure self-efficacy in the contemporary era of 
diabetes technologies. One article described modifying the SED instrument to include current 
aspects of type 1 diabetes (pump therapy),71 yet a lack of instruments to measure self-efficacy 
pertaining to current diabetes technology is a pertinent limitation of the available instruments. A 
caveat to this is that not all articles identified through the integrative review or the original 
articles describing the instruments included a description of survey items. While advances in 
diabetes technology aim to improve self-management and glycemic control, it is important to 
assess an individual’s confidence in the ability to use such devices. Currently available self-
efficacy instruments would provide added benefit with the inclusion of assessments of self-
efficacy related to technology advancements in the contemporary diabetes era. Alternatively, 
clinicians and researchers could design instruments to specifically evaluate youth and parent 
confidence related to using diabetes technologies, such as continuous glucose monitors, which 
are increasingly relevant with the advent of the Artificial Pancreas Project.113 
Implications 
 Reliable and valid instruments to measure a concept of interest, such as self-efficacy, are 
essential for quality research and use in clinical care.  The use of well-constructed measurements 
will confirm potential results and enhance opportunities to generalize findings to populations at 
large.  This review is relevant to research, clinical care, and diabetes education of youth with 
type 1 diabetes because it identified several reliable and valid instruments to evaluate self-
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efficacy, an important component of diabetes self-management.  The available instruments vary 
in length, with respect to the targeted participant age group, and whether caregivers are the focus 
of the assessment.  Although certain studies may not have explicitly stated reliability or validity 
data, the psychometrics were identified in articles published prior to the 2003-2013 timeframe; 
however, caution is warranted if applying these psychometric properties across time and in 
different groups.98 
 This integrative review identified various gaps that could guide future research and 
instrument development.  This search was restricted to the past decade and, thus, was not 
exhaustive.  Of particular note is the absence of self-efficacy instruments or proxy reports that 
focus on peers of youth with type 1 diabetes. During the teenage years, adolescents often seek 
support of friends and peers, with less emphasis on support from the family unit.111 Therefore, it 
would be important to assess peer self-efficacy in assisting friends with type 1 diabetes in 
various diverse settings.  Additionally, in all youth, and specifically younger children, it would 
be beneficial to identify valid and reliable instruments to measure self-efficacy in other 
caregivers, e.g. grandparents.  Such research across other care providers and possibly peers could 
help to identify knowledge deficits and avenues for education of important groups for social 
support of youth with type 1 diabetes.  Future studies are needed to implement self-efficacy 
measurements in minority populations, as well as international samples, to further assess the 
psychometric properties of these instruments and to broaden their application to youth with type 
1 diabetes globally. Additionally, instruments to measure the construct of self-efficacy in the 
current era of advanced diabetes technologies, including use of insulin pumps and continuous 
glucose monitoring technologies, appear to be needed. A lack of instruments to measure self-
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efficacy related to diabetes technologies implies that the available self-efficacy instruments need 
to be adapted or new instruments need to be developed to be relevant in the contemporary era. 
In selecting an instrument to measure self-efficacy in the pediatric population with type 1 
diabetes and their caregivers, the clinical or research team must contemplate various factors. One 
must consider the population (i.e. youth, parents, school nurses, camp counselors), length of the 
scale, available psychometric data, availability of the measure, and the particular aspect related 
to diabetes management that the self-efficacy scale measures (i.e. diet, physical activity, general 
diabetes self-efficacy). Having specific criteria will guide the instrument selection. Additionally, 
when identifying instruments for use in the pediatric population and in the context of diabetes 
education, it is important to consider how the concept of self-efficacy can span throughout 
childhood and at what age youth are able to understand and answer questions related to self-
efficacy. Many studies identified in this integrative review had youth ≥10 years old complete the 
various instruments, including the self-efficacy assessments; however, some studies had 
participants as young as 8 years old. A final consideration when evaluating instruments for use 
with caregivers is to determine whether the purpose of the instrument is to assess the caregiver’s 
own perception of confidence related to diabetes management or whether the instrument assesses 
the caregiver’s confidence in the child’s self-care, an important component to keep in mind when 
measuring the construct of self-efficacy.   
 In conclusion, when selecting an instrument to measure self-efficacy in youth with type 1 
diabetes and their caregivers, it is important to remember that one’s perceived ability for diabetes 
self-management reflects a constellation of behaviors. Furthermore, improvements in intensive 
therapy options can add to self-management challenges as diabetes technologies continue to 
evolve, reinforcing the need to capture self-efficacy. The evolvement of type 1 diabetes 
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technologies will require either making modifications to existing self-efficacy instruments or 
developing new instruments altogether; evaluation of the psychometric properties of these 
instruments will be necessary. It is essential to select an instrument that is appropriate, 
acceptable, feasible, and responsive to both the needs of the patient and the clinician or 
researcher as well as an instrument that it is valid, reliable, and precise in measurement to ensure 
clinical and research integrity are maintained. 
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Chapter 4: Youth and Parent Measures of Self-Efficacy for Continuous Glucose Monitoring 
(CGM): Survey Psychometric Properties 
Objective: The purpose of this study was to investigate the psychometric properties of a novel 
instrument to measure self-efficacy related to continuous glucose monitoring in youth with type 
1 diabetes and their parents. This evaluation also assessed the predictive validity of the CGM-
Self-Efficacy (CGM-SE) instrument scores upon CGM use and hemoglobin A1c (HbA1c).  
Research Design and Methods: Study participants included 120 youth with type 1 diabetes for 
≥ 1 year who were enrolled in a 2-year randomized clinical trial (RCT) comparing CGM use 
with and without the addition of a family-focused CGM behavioral intervention. Youth and 
parents completed the CGM-SE instrument at randomization after a 1-week run-in period to 
assess CGM tolerability and again at 6 months. Analysis of predictive validity excluded the 
intervention group and included 61 youth in the control group to assess CGM use and HbA1c 
outcomes 3 and 6 months after randomization. 
Results: At study entry, youth were on average 12.7 ± 2.7 years old with a mean diabetes 
duration of 6.1 ± 3.6 years and mean HbA1c of 8.0 ± 0.8%; mean blood glucose (BG) 
monitoring frequency was 6.8 ± 2.4 times/day and 84% pump received therapy. The CGM-SE 
had acceptable internal consistency (Cronbach’s α = 0.80 for youth; 0.82 for parents). 
Exploratory factor analysis yielded two factors for both the youth and parent surveys; “home” 
and “away” were the two factors for the youth survey and “relational” and “technical” for the 
parent survey. Youth reporting higher baseline CGM self-efficacy (score > 80) had statistically 
significantly greater CGM use and lower HbA1c after 3 and 6 months compared to youth 
reporting lower baseline CGM self-efficacy (score ≤ 80). 
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Conclusions: The novel CGM-SE instruments appear to have strong psychometric properties. 
CGM self-efficacy may offer an opportunity to assess the likelihood of CGM adherence and 
glycemic improvement in youth with type 1 diabetes in clinical and research settings. 
The current era of intensive insulin therapy places substantial demands upon children and 
adolescents with type 1 diabetes along with their parents. Intensive insulin therapy requires 
numerous self-care behaviors, which are particularly evident in the use of continuous glucose 
monitoring (CGM) technologies, in order to maintain glycemic control. The JDRF CGM RCT 
yielded significantly improved glycemic outcomes without severe hypoglycemia in adults; 
however, children and adolescents only demonstrated improved glycemic control with consistent 
CGM use.13,17 Thus, there has been substantial interest in uncovering approaches to encourage 
consistent CGM use in the pediatric population. Specifically, we were interested in 
understanding how self-efficacy may relate to CGM use in children and teens with type 1 
diabetes and their parents. 
Self-efficacy, a central part of Bandura’s Social Cognitive Theory, is an individual’s 
perceived ability to carry out a certain behavior.22,114 Self-efficacy can augment one’s motivation 
to perform certain tasks21 and can be an important indicator of health behavior change.27 
Measuring self-efficacy is an integral part of the predictive evaluation of whether an individual 
will carry out a specific task and the level of perseverance they will exert when faced with 
challenges or barriers. Self-efficacy also influences outcome expectations or the result an 
individual anticipates that his/her actions will generate.24 Higher levels of self-efficacy often 
parallel more positive outcomes expectations.24  
Given the exceeding demands that type 1 diabetes self-management imposes on patients 
and families, particularly with the advancements in diabetes technologies, self-efficacy is an 
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important construct to evaluate in youth with type 1 diabetes and their caregivers. Type 1 
diabetes management necessitates a complex orchestration of family and self-care tasks. 
Specifically, optimal diabetes management requires adherence to frequent blood glucose 
monitoring as well as balancing food and exercise with timely insulin administration. 
Additionally, youth and their caregivers may use advanced diabetes technologies, such as CGM, 
to maintain glycemic control. Use of CGM can help improve glycemic control in youth; yet 
consistent CGM use is challenging due to the potentially increased burden of wearing the device 
regularly.13 High self-efficacy, or strong perceived ability to make positive health behavior 
changes despite challenges,24 may facilitate complex behaviors like CGM use in youth with type 
1 diabetes. Given the challenges of consistent CGM use in youth with type 1 diabetes, it is 
important to determine whether self-efficacy is a factor in consistent CGM use, and whether the 
level of self-efficacy predicts CGM use, and, in turn, glycemic outcomes. Evaluating CGM self-
efficacy in both youth and parents is particularly important considering the level of support and 
family involvement that are necessary for diabetes self-care tasks with intensive insulin therapy 
and advanced diabetes technologies. The ability to measure self-efficacy related to CGM use 
may help the pediatric multidisciplinary team to identify those youth and parents who may 
benefit from additional education and support. However, there is a paucity of published research 
in the area of assessing self-efficacy related to CGM in youth with type 1 diabetes.  
This first aim of this study was to evaluate the psychometric properties of a novel 
instrument designed to assess self-efficacy related to CGM in children and adolescents with type 
1 diabetes and their parents. The second aim of the study was to assess the predictive validity of 
the CGM-SE in a subset of participants to determine whether CGM self-efficacy predicts CGM 
use and subsequent glycemic control. 
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Research Design and Methods 
Study Population 
This study is part of a larger 2-year randomized clinical trial (RCT) comparing CGM use 
with and without the addition of a family-focused CGM behavioral intervention. Initially, the 
Dexcom SEVEN PLUS CGM was used in the study. Patients transitioned to the Dexcom G4 
when it became available on the market. Study participants were 120 youth with type 1 diabetes 
and their parents; they were randomized in a 2-year RCT and followed at a tertiary care center in 
the northeastern United States. Eligibility criteria included youth ages 8-17 years with type 1 
diabetes ≥ 1 year; established use of intensive insulin therapy (pump or multiple daily 
injections); insulin dose of ≥ 0.5 units/kg/day; blood glucose (BG) monitoring frequency of ≥ 4 
times/day; hemoglobin A1c (HbA1c) 6.5%-10%; no consistent CGM use (defined as 6+ 
days/week) in the previous 6 months; and anticipation for ongoing care at the diabetes center. 
Parents provided written informed consent and youth provided written informed assent prior to 
initiating any study procedures. The Institutional Review Board at the tertiary care center 
approved the study protocol and the investigator’s university granted reciprocity.  
The current report utilizes the entire sample of 120 youth at baseline to evaluate the 
CGM-SE surveys (Aim 1) and the 61 participants randomized to the control group to assess the 
predictive validity of the CGM-SE survey on CGM wear and subsequent glycemic control (Aim 
2).  
Data Collection 
The electronic medical record, parent-youth interviews, and blood glucose meter 
downloads provided clinical and diabetes management data at each of the baseline, 3, and 6 
month study visits as part of the larger study. The CGM data were obtained at the 3 and 6 month 
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visits by downloading the data stored on the CGM device. Youth and parents completed the 
following questionnaires at the baseline and 6 month study visits: the Pediatric Quality of Life 
Inventory (PedsQL) Generic Core Scales and the Type 1 Diabetes Module,115,116 the Diabetes 
Management Questionnaire (DMQ),117 the Problem Areas in Diabetes Survey-Parent Revised 
and Pediatric Version (PAID-PR/PAID-Peds),118,119 the State-Trait Anxiety Inventory (STAI) 
and the STAI for Children (STAIC),120,121 and the Center for Epidemiologic Studies Depression 
Scale (CES-D) for parents and the CES-D for Children (CES-DC).122,123 All measures have been 
demonstrated to be reliable and valid for use in populations with diabetes (see below). 
Immediately following the baseline study visit, youth wore the CGM for a 1-week run-in period 
to assess CGM tolerability. At the end of the 1-week run-in period, participants were randomized 
and youth and parents completed the CGM-SE instrument developed for the 2-year RCT. 
Measures 
Development of the CGM Self-Efficacy Instrument (CGM-SE) 
A pediatric multidisciplinary diabetes team, experienced in clinical research and CGM 
use, developed the self-efficacy instrument items following a literature review. Item refinement 
occurred through pre-testing and cognitive interviewing in youth and parents prior to the 2-year 
RCT. Items assessed the confidence of youth and parents to manage the technical and behavioral 
aspects of CGM use. The stem of the items stated, “I am sure that I can…”. There are two 
versions of youth instruments based on age (ages 8-12: 11 items; ages 13+: 15 items) and one 
version for parent instrument (14 items). The 4 additional items on the version for ages 13+ 
address performance of more complex tasks, such as downloading CGM data and making insulin 
adjustments based on CGM data. All item responses are scored on a 7-point Likert scale (0 = 
strongly disagree, 6 = strongly agree). The total score is obtained by computing the mean of all 
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items, multiplying the mean by 100, and then dividing by 6. Scores can range from 0-100, with 
higher scores reflecting higher self-efficacy. Each version requires < 5 minutes for completion.  
Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales and Type 1 Diabetes 
Module115,116  
The PedsQL Generic Core Scales (23 items) and PedsQL Type 1 Diabetes Module (28 
items) assess generic and diabetes-specific youth quality of life over the past month. Items are 
scored on a 0-4 Likert scale (0=never, 1=almost never, 2=sometimes, 3=often, 4=almost always) 
with higher scores indicating greater quality of life. The youth instrument is a self-report of 
youth quality of life; the parent instrument is a proxy report of youth quality of life. The 
Cronbach’s α for the current sample was the following: PedsQL Generic Core Scales (youth α = 
0.94; parents α = 0.90) and PedsQL Type 1 Diabetes Module (youth α = 0.91; parents α = 0.86). 
In a sample of youth with T1D and T2D, the published literature has reported a Cronbach’s α for 
the PedsQL Generic Core Scales of 0.88 for youth and 0.89 for parents.116 For the PedsQL Type 
1 Diabetes Module, the Cronbach’s α has ranged from 0.63-0.77 for the subscales for youth and 
0.81-0.84 for parents.116 
Diabetes Management Questionnaire (DMQ)117 
The DMQ assesses adherence to daily diabetes self-management tasks. Items are 
applicable to both injection-based therapy and insulin pump therapy. Both youth and parent 
measures consist of 20-items based on a 5-point Likert scale ranging from “almost never” to 
“almost always”, with higher scores indicating higher levels of adherence to diabetes 
management. The youth survey is a self-report adherence; the parent survey is a proxy report of 
adherence. The Cronbach’s α for the current sample was α = 0.67 for youth and α = 0.73 for 
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parents. In a sample of youth with T1D and their parents, the published literature has reported 
Cronbach’s α of 0.77 for youth and 0.81 for parents.124 
Problem Areas in Diabetes Survey-Parent Revised (PAID-PR)118 and Pediatric (PAID-
Peds)119 versions 
The PAID-PR (18 items) and PAID-Peds (20 items) assess diabetes burden over the past 
month. Item responses are on a 5-point Likert scale (0 = agree, 4 = disagree). Higher scores 
indicate more burden related to diabetes management.125,126 The PAID-PR is a self-report of 
parent burden; the PAID-Peds is a self-report of youth burden. The Cronbach’s α for the current 
sample was α = 0.94 for youth and α = 0.90 for parents. The published literature has reported a 
Cronbach’s α of 0.87 for the PAID-PR118 and 0.93 for the PAID-Peds in a sample of youth with 
T1D.119 
State-Trait Anxiety Inventory (STAI)121 and STAI for Children (STAIC)120 
The STAI (40 items) and STAIC (40 items) assess feelings of anxiety “right now” (state 
anxiety) and in general (trait anxiety). Youth responses are on a 3-point Likert scale (1 = hardly 
ever, 3 = often) and parent responses are on a 4-point Likert scale (1 = not at all, 4 = very much 
so). Higher scores indicate more symptoms of anxiety. The STAI is a self-report of parent 
anxiety; the STAIC is a self-report of youth anxiety. The Cronbach’s α for the current sample 
was α = 0.93 for youth and α = 0.96 for parents. In a sample of parents of youth with T1D, the 
published literature has reported Cronbach’s α of 0.92-0.93 for the STAI.127 In a sample of youth 
with chronic disease, including diabetes, the published literature has reported Cronbach’s α 
ranging from 0.89 to 0.93 for the STAIC.128 
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Center for Epidemiologic Studies Depression Scale (CES-D)123 and CES-D for Children 
(CES-DC)122 
This depression scale has 20-items. The youth response options are on a 4 point Likert 
scale ranging from 0 = not at all to 3 = a lot. The parent response options range from 0 or “rarely 
or none of the time (< 1 day/week)” to 3 or “most or all of the time (5-7 days/week)”.  Higher 
scores reflect higher depressive symptoms over the past week. The CES-D is a self-report of 
parent depressive symptoms; the CES-DC is a self-report of youth depressive symptoms. A 
mental health professional followed-up with the family according to the RCT study protocol if 
youth scored ≥ 15 or if parents scored ≥ 16. These validated measures have been used in other 
ongoing studies involving youth with type 1 diabetes and their parents.127,129,130 The Cronbach’s 
α for the current sample was α = 0.90 for youth and α = 0.91 for parents. In a sample of parents 
of youth with T1D, the published literature has reported Cronbach’s α of 0.91 for the CES-D.127 
The study that validated the CES-DC in youth reported a Cronbach’s α of 0.89.122 
Glycemic Control 
HbA1c was measured uniformly at baseline and 3 and 6 months after randomization 
using an assay standardized to the Diabetes Control and Complications Trial (reference range 
4.0-6.0%; Roche Diagnostics, Indianapolis, IN).  
CGM Use 
CGM data were downloaded at study visits using Dexcom™ proprietary software. We calculated 
the amount of weekly CGM use by averaging the total hours of wear during the 4 weeks 
preceding the 3 and 6 month visits. The baseline CGM wear consisted of the total hours of CGM 
wear during the 1-week run-in period. CGM use could range from 0 to 168 hours/week. We also 
created a categorical variable of CGM use with three categories 0-2 days (≤ 48 hours), 3-5 days 
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(> 48-120 hours), and 6-7 days (> 120-168 hours) based upon previously identified amounts of 
CGM use associated with glycemic outcomes.17,131 Rules for missing data, determined by the 
study team, consisted of using the average hours of CGM wear for the preceding study visit, if 
there were missing data for the 3 and 6 month visits. A total of three participants did not have 
data for the preceding visit so their data from the subsequent visit were used. A similar approach 
was used for HbA1c data. 
Statistical Analysis 
Data were analyzed using SAS version 9.2 for Windows (SAS Institute, Cary, North 
Carolina). Demographic and clinical characteristics are presented as mean ± SD, median, or 
percentage.  
Psychometric analyses: Cronbach’s α was used to assess internal consistency or the level to 
which the items are conceptually similar.105 Item-to-total correlations for each of the items in the 
youth and parent instruments were calculated and analyzed to determine the interrelatedness of 
the items.112 To evaluate the psychometric properties of the CGM-SE across the sample age 
range, and given the two different youth instrument versions based upon age, we performed 
separate analyses by age. We did not assess test-retest reliability because we did not anticipate 
that self-efficacy would be a stable construct in youth starting CGM. We assessed criterion 
validity of the CGM-SE for all youth and parent participants at baseline. Pearson correlations of 
the CGM-SE with the PedsQL (general and diabetes specific) and the DMQ instruments assessed 
convergent validity and correlations with the PAID-PR/PAID-Peds, STAI/STAIC, and CES-
D/CES-DC assessed discriminant validity.  
Construct validity was assessed by exploratory factor analysis for the youth instrument 
(all youth completing items 1-11) and the parent survey (items 1-14) completed at baseline. The 
	   72	  
Kaiser-Meyer-Olkin measure of sampling adequacy test was used to evaluate whether the sample 
was appropriate for factor analysis. The factor analysis for the youth version combined the 
uniform youth items 1-11 but did not include the additional items on the 13+ version because of 
the small sample size. The Principal Components Analysis (PCA) method was used to extract the 
factors. Criteria used to determine the number of factor extracted included the Scree Test and 
Kaiser’s criteria that recommends retaining factors with Eigenvalues > 1.132 To facilitate factor 
interpretation, factors were rotated using the Promax oblique rotation method, which assumes the 
factors are related.132 The rotated factor pattern matrix was assessed to identify the items that 
loaded the highest on each of the factors. The research team analyzed the items and factor 
loadings to label and assign meaning to the factors.  
Predictive validity analyses: To assess predictive validity, we included the 61 participants from 
the control group of the RCT as CGM self-efficacy was expected to change among intervention 
subjects. We used t-tests and chi-square tests to compare baseline participant characteristics 
between those in the control group (n = 61) and those in the experimental group (n = 59). In 
analyses (correlations/regressions) of the predictive validity of the CGM-SE, we examined CGM 
use and HbA1c outcomes 3 and 6 months after randomization.  
Paired t-tests were used to assess differences between baseline and 3- and 6-month 
variables such as CGM use and HBA1c outcomes in the control group.  
As there is no a priori level of adequate CGM self-efficacy to affect CGM use, we 
explored the distributions of youth and parent CGM-SE scores according to the 3 recognized 
categories of CGM use. Specifically, we used ANOVA to assess differences in baseline CGM-
SE scores according to 3- and 6-month CGM use considered as a categorical variable (≤ 2 days, 
3-5 days, 6+ days). When looking at the self-reported CGM self-efficacy levels at each of the 
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CGM use categories, there appeared to be a separation by youth reporting a CGM-SE score over 
80. Based upon these observations, baseline CGM-SE scores were grouped into 2 categories. We 
identified a self-efficacy score of 80 as a threshold, and then categorized youth and parent 
baseline self-efficacy scores in groups of ≤ 80 and > 80. Independent groups (pooled) t-tests 
were used to compare 3- and 6-month CGM use and HbA1c outcomes by CGM-SE category. 
Spearman’s correlations determined predictive validity of the youth and parent baseline 
self-efficacy score with HbA1c and CGM use at 3 and 6 months for the 61 control participants. 
Further correlations assessed the relationship of youth and parent self-efficacy scores with other 
baseline characteristics and change in self-efficacy from baseline to 6 month to determine 
whether self-efficacy changes were based on CGM use, which would support enactive 
attainment or performance accomplishments as a source of self-efficacy.22  
To confirm the predictive value of youth baseline CGM self-efficacy on both CGM use 
and HbA1c outcomes at 3 and 6 months, multiple regression was used, controlling for youth age 
and duration of type 1 diabetes. Additional multiple regression was performed to determine 
potential predictors of HbA1c at 3 and 6 months based on age, diabetes duration, CGM wear at 3 
and 6 months, and youth baseline CGM self-efficacy. A p value of ≤ 0.05 defined significance. 
Results 
Participant Characteristics 
Overall, youth (N = 120) were on average 12.7 ± 2.7 years old, 49% were female, and 
89% lived within 2- parent households. Youth had mean diabetes duration of 6.1 ± 3.6 years, 
checked BG levels on average 6.8 ± 2.4 times daily, and the majority (84%) received insulin 
pump therapy. Eighty-three percent of participating parents were mothers. The younger group 
was composed of 68 youth < 13 years old and the older group was composed of 52 youth; 
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HbA1c was similar in both age groups with mean value of 7.9% ± 0.8% for youth < 13 and 8.0 ± 
0.8% for youth ≥ 13. Participant characteristics are presented in Table 1. 
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Table 1. Baseline participant characteristics 
 All Youth 
(N = 120) 
Youth <13 
(n = 68) 
Youth ≥13 
(n = 52) 
Age (years) 12.7 ± 2.7 
(8.0-17.9) 
10.8 ± 1.4 
(8.0-12.9) 
15.3 ± 1.5 
(13.0-17.9) 
Gender (% male) 51 49 54 
Race/ethnicity (% white) 95 94 96 
Gender of participating parent (% female) 83 87 79 
Family structure (% 2-parent home) 89 87 92 
Highest level of parent education (%) 
   High school/GED 
   Junior/technical college or associate’s degree                                        
   College degree 
















35                 
29 
Average annual household income (%) 
   <$30,000 
   $30,000-$49,000 
   $50,000-$99,000 
   $100,000-$149,000 



















Health insurance (%) 
   Private or military 










Age at type 1 diabetes diagnosis (years) 6.6 ± 3.6 
(0.7-15.8) 
5.9 ± 2.8* 
(0.7-11.5) 
7.5 ± 4.3* 
(0.8-15.8) 
Type 1 diabetes duration (years) 6.1 ± 3.6 
(1.0-15.9) 
4.9 ± 2.6† 
(1.1-10.1) 
7.7 ± 4.0† 
(1.0-15.9) 
Insulin dose (U/kg/day) 0.9 ± 0.3 
(0.4-1.9) 
0.9 ± 0.3 
(0.5-1.9) 
0.9 ± 0.2 
(0.4-1.6) 
Blood glucose monitoring (times/day) 6.8 ± 2.4 
(1-12) 




Insulin regimen (%) 
   Pump 










HbA1c (%) 8.0 ± 0.8 
(6.2-11.1) 
7.9 ± 0.8 
(6.2-11.1) 
8.0 ± 0.8 
(6.4-10.3) 
Data are means ± SD (range) or %; * p = 0.02; †p < 0.0001; ‡p = 0.0002 
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CGM-SE Scores 
Youth and parents reported relatively high self-efficacy at the baseline assessment following 1 
week of CGM wear (Table 2 and Figure 1). Mean baseline CGM-SE scores were 87 ± 10 for 
youth (ages 8-12: 87 ± 11, ages ≥ 13: 88 ± 9) and 84 ± 10 for parents. In additional analyses, 
youth scores were combined due to their similar distributions. As parental responses on the 
CGM-SE were essentially identical when comparing responses of parents of youth < 13 and 
responses of parents for youth ≥ 13 by distribution, mean, and median, all parent scores are 
presented together. While there was no statistically significant correlation between youth and 
parent scores (r = 0.13, p = 0.15) or between youth and parent scores when youth were stratified 
by age (ages 8-12: r = 0.19, p = 0.13; ages ≥ 13: r = 0.05, p = 0.72), youth and parent scores 
were each significantly correlated with a number of demographic variables and diabetes 
management variables. Youth with lower mean glucose levels from meter download reported 
more confidence in CGM use (all youth: r = -0.30, P = 0.0009; ages 8-12: r  = -0.27, p = 0.03; 
ages ≥13 r = -0.35, p = 0.01) (Table 3). Parents of youth diagnosed at a younger age reported 
higher CGM self-efficacy (r = -0.22, p = 0.01) and parents of youth with higher HbA1c levels 
reported higher CGM self-efficacy (r = 0.27, p = 0.003) (Table 3). Neither youth or parent self-
efficacy scores differed according to family structure or insulin regimen; scores were not related 
to youth age, duration of diabetes, or frequency of BG monitoring. 
Table 2. Baseline CGM-SE total scores for all participants  
CGM-SE Score  All Youth 
(N = 120) 
Youth <13 
(n = 68) 
Youth ≥13 
(n = 52) 
Parent 
(N = 119) 
Mean ± SD 87 ± 10 87 ± 11 88 ± 9 84 ± 10 
Median 90 89 90 85 
Range 53-100 53-100 63-100 61-100 
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Figure 1. Baseline CGM-SE score distribution for all youth and parents 
 
Table 3. Correlations of baseline age, clinical characteristics, quality of life, adherence, problem 
areas in diabetes, anxiety, and depression with baseline CGM-SE score for all youth 
 All Youth Youth <13 Youth ≥13 Parent 
Age 0.14 0.16 0.14 -0.10 
Diabetes duration 0.01 0.18 -0.24 0.15 
Age at diagnosis 0.09 -0.09 0.27 -0.22* 
HbA1c -0.07 -0.01 -0.18 0.27* 
Blood glucose monitoring -0.11 -0.09 -0.11 0.06 
Mean blood glucose -0.30* -0.27* -0.35* 0.18 
DMQ 0.14 0.20 0.10 0.19* 
PedsQL 
     General 












  0.25* 
PAID-PR/PAID-Peds -0.05 -0.02 -0.12 -0.08 
STAI/STAIC 
     State 













CES-D/CES-DC -0.12 -0.07 -0.21 0.02 
*p ≤ 0.05 
Legend for abbreviations: Diabetes Management Questionnaire (DMQ), Pediatric Quality of Life 
Inventory (PedsQL) Generic Core Scales and Type 1 Diabetes Module, Problem Areas in Diabetes-Parent 
Revised (PAID-PR) and Pediatric (PAID-Peds), State-Trait Anxiety Inventory (STAI) and STAI for 
























CGM Self-Efficacy Score 
Younger Youth (<13) 
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Psychometric Properties of the CGM-SE Survey (Aim 1) 
The 11-item version for youth < 13, the 15-item version for youth ≥ 13, and the 14-item 
parent version demonstrated high internal consistency (Cronbach’s α = 0.80, 0.80, and 0.82, 
respectively). The instruments demonstrated good item-to-total correlations with almost all items 
falling within the recommended range of 0.20-0.80 for scale development112 (Table 4). The 
majority of items were > 0.40 for youth (range 0.28 - 0.61 for youth aged 8-12; range 0.26 - 0.63 
for youth ≥ 13; range 0.34 - 0.58 for parents). Items < 0.40 (2 items for youth aged 8-12; 4 items 
for youth aged ≥ 13; 1 item for parents) were retained due to clinical relevance. 
Convergent validity was established for the older youth CGM-SE, as evidenced by 
statistically significant positive correlations with the PedsQL Generic Core score (r = 0.32, p = 
0.02) (Table 3). Similarly, convergent validity was established for the parent CGM-SE given the 
positive correlations with the PedsQL diabetes specific module (r = 0.25, p = 0.0073) and the 
adherence measure, the DMQ (r = 0.19, p = 0.037) (Table 3). As these correlations were weak, 
their clinical relevance requires further evaluation. There were no statistically significant 
correlations between the youth and parent CGM-SE with the PAID-PR/PAID, STAI/STAIC, or 
CES-D/CES-DC supporting discriminant validity. 
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Table 4. Internal consistency for CGM-SE: Item-to-total correlations and Cronbach’s α 
Items 
“I am sure I can…” 
Youth <13 Youth ≥13 Parents 
Insert sensor 0.28 0.28 0.34 
Calibrate sensor 0.58 0.62 0.51 
Keep the receiver 0.32 0.41 0.58 
Look at the receiver 0.48 0.59 0.53 
Respond to CGM alarms 0.42 0.48 0.50 
Charge the CGM receiver 0.61 0.54 0.51 
Ask for help with CGM 0.49 0.55 - 
Wear/work with child to wear CGM at 
least 6 days a week 
0.61 0.26 0.45 
Talk to my parents if having a hard time 
using CGM 
0.43 0.38 - 
Respond to CGM alarms at school 0.55 0.55 - 
Respond to CGM alarms when with 
friends 
0.51 0.63 - 
Download CGM data - 0.17 0.53 
Problem-solve technical difficulties with 
device 
- 0.60 0.53 
Adjust insulin dose based on real-time 
data 
- 0.55 0.52 
Adjust insulin dose based on 
downloaded CGM data 
- 0.46 0.52 
Speak with medical team if needing help 
with CGM 
- - 0.50 
Share CGM responsibilities with child - - 0.42 
Be encouraging and supportive working 
with child on CGM 
- - 0.41 
Cronbach’s α 0.80 0.80 0.82 
Items are shortened for ease of presentation 
 
CGM-SE Factor Analysis 
The Kaiser-Meyer-Olkin test (KMO), an overall measure of sampling adequacy, had a 
value of 0.77 for youth and 0.82 for parents, which indicated the sample sizes were sufficient and 
the data acceptable for factor analysis on the baseline 11-item youth and 14-item parent CGM-
SE instruments.132 Factors were extracted using the PCA method. Promax (oblique) rotation was 
used because the items forming the factors were theoretically related and measured elements of 
CGM self-efficacy.132 Additionally, oblique rotations are commonly used in research that 
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evaluates human behaviors.132 Factor analysis resulted in two factors for the youth version and 
two factors for the parent version with factor loadings > 0.40, except for item five on the youth 
version (see below) (Table 5 and 6).  The items that loaded highest on factor 1 and factor 2 for 
each version embodied common themes, thus providing the basis for meaningful factor 
interpretation.132  
Table 5. Rotated factor loadings of the youth CGM-SE  
Items Factor 1 Factor 2 
Insert sensor 0.06 0.42 
Calibrate sensor 0.51 0.33 
Keep the receiver 0.80 -0.29 
Look at the receiver 0.71 0.03 
Respond to CGM alarms 0.35 0.35 
Charge the receiver 0.22 0.67 
Ask for help with CGM -0.14 0.90 
Wear CGM at least 6 days a week 0.62 0.21 
Talk to my parents if having a hard time using 
CGM 
-0.05 0.73 
Respond to CGM alarms at school 0.63 0.17 
Respond to CGM alarms when with friends 0.74 0.04 
Conducted exploratory factor analysis using PCA as extraction method (SAS default). Rotation 
method: Promax. Items are shortened for ease of presentation; related factor loadings are in bold. 
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Table 6. Rotated factor loadings of the parent CGM-SE  
Items Factor 1 Factor 2 
Insert sensor 0.02 0.52 
Work with child to calibrate sensor 0.47 0.30 
Work with child to keep the receiver 0.76 0.11 
Work with child to look at the receiver 0.78 0.03 
Work with child to respond to CGM alarms 0.83 -0.04 
Ensure CGM receiver stays charged 0.49   0.28 
Speak with medical team if needing help with 
CGM 
0.76 -0.00 
Download CGM data 0.04 0.74 
Problem-solve technical difficulties with device 0.27 0.53 
Adjust insulin dose based on real-time data -0.00 0.77 
Adjust insulin dose based on downloaded CGM 
data 
-0.12 0.87 
Share CGM responsibilities with child 0.46 0.19 
Work with child to wear CGM every day 0.87 -0.15 
Be encouraging and supportive working with 
child on CGM 
0.77 -0.12 
Conducted exploratory factor analysis using PCA as extraction method (SAS default). Rotation 
method: Promax. Items are shortened for ease of presentation; related factor loadings are in bold. 
 
We labeled factor 1 (seven items) for the youth version “away” because the items that 
loaded highest on this factor represented CGM tasks the youth would likely perform away from 
the home environment. We labeled factor 2 (four items) for the youth version “home” because 
these items describe tasks or behavioral aspects related to CGM wear that the youth would likely 
do within the home environment. Item five (“Respond to the CGM receiver alarms”) on the 
youth instrument had a factor loading of 0.35 on both factor 1 and factor 2. We retained item five 
on the youth factor 1 because of its consistency with other items on factor 1. There was good 
internal consistency for the youth factor 1 (Cronbach’s α = 0.81). The internal consistency was 
not as high for youth factor 2 (Cronbach’s α = 0.62) in relation to the low item to total 
correlation of item one (“Insert the CGM sensor”); however, we retained this item for its clinical 
relevance. The two youth factors (r = 0.51, p <0.0001) were correlated. 
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We labeled factor 1 (nine items) for the parent version “relational” because these items 
represent working with the youth for CGM wear and factor 2 (five items) “technical” because 
these items represent technical aspects related to performing CGM tasks. There was good 
internal consistency within the two factors for the parent version (factor 1 Cronbach’s α = 0.86; 
factor 2 Cronbach’s α = 0.76). The two parent factors (r = 0.37, p < 0.0001) were correlated. 
Predictive Validity of the CGM-SE (Aim 2) 
Participant Characteristics 
Control group participants (48% female) included in the predictive validity analyses 
consisted of 61 youth with type 1 diabetes. Their mean age was 12.7 ± 2.9 years old; they had a 
mean diabetes duration of 6.3 ± 3.8 years, mean daily insulin dose was 0.88 ± 0.3 units/kg/day, 
and mean BG monitoring frequency of 7.0 ± 2.6 times daily. The majority (80%) received pump 
therapy (Table 7). Characteristics of these control group participants were similar to the 
intervention participants.  
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Table 7. Participant characteristics for youth in the control group 
 
Control Group Youth 
 (n = 61) 
Age (years) 12.7 ± 2.9 (8.0-17.9) 
Gender (% male) 52 
Race/ethnicity (% white) 93 
Gender of participating parent (% female) 87 
Family structure (% 2-parent home) 87 
Highest level of parent education (%) 
   High school/GED 
   Junior/technical college or associate’s degree 
   College degree 






Average annual household income (%) 
   <$30,000 
   $30,000-$49,000 
   $50,000-$99,000 
   $100,000-$149,000 







Health insurance (%) 
   Private or military 




Age at type 1 diabetes diagnosis (years) 6.3 ± 3.5 (0.7-15.8) 
Type 1 diabetes duration (years)  6.3 ± 3.8 (1.2-15.9) 
Insulin dose (U/kg/day) 0.9 ± 0.3 (0.5-1.9) 
Blood glucose monitoring (times/day) 7.0 ± 2.6 (1-12) 
Insulin regimen (%) 
   Pump 





   Baseline 
   3 month 
   6 month 
 
7.9 ± 0.9 (6.2-11.1) 
7.7 ± 0.8 (6.1-10.1) 
7.8 ± 0.8 (6.0-10.6) 
 
Data reported as means ± SD (range) or % 
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CGM Use 
Randomization required demonstration of CGM wear during the 1-week run-in period. 
During the run-in week, the mean CGM use for the 61 controls was 128.7 ± 18.9 hours/week 
(range 67.6-151.6); after 3 months mean CGM use was 99.6 ± 49.0 hours/week (range 0-157.3); 
and after 6 months mean CGM use 82.5 ± 55.6 hours/week (range 0-156.8) (Figure 2). CGM use 
data were unavailable for only one participant due to multiple missed visits. Not unexpectedly, 
the mean hours of CGM use decreased over time with a statistically significant difference in 
baseline to 3 month CGM wear (p < 0.0001), 3 month to 6 month CGM wear (p = 0.0013), and 
baseline to 6 month (p < 0.0001).  
Figure 2. CGM use (hours/week) for baseline, 3 month, and 6 month visits for control group 
participants. The top and bottom of the boxes denotes the 25th and 75th percentiles, the line 
represents the median, and the dot represents the mean.  
 
Glycemic control 
At baseline, mean HbA1c for the 61 controls was 7.9 ± 0.9% (range 6.2-11.1), after 3 























 Visit Month  
Median = 134.3 
Mean = 128.7 
Median = 114.4 
Mean = 99.6 
Median = 93.7 
Mean = 82.5 
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was 7.8 ± 0.8% (range 6.0-10.6) (Table 7). There was only one missing HbA1c value at 3 
months due to missed visits. There was a statistically significant difference between baseline 
versus 3 and 6 month HbA1c (p = 0.03 and p = 0.01, respectively); no statistically significant 
difference was observed between the 3 month and 6 month HbA1c values. 
CGM Self-Efficacy 
 At baseline, the mean CGM-SE score for the 61 youth in the control group was 87 ± 11 
compared to 86 ± 12 for the 6-month visit (Table 8 and Figure 3). There was no statistically 
significant difference observed between the youth baseline and 6 month CGM-SE scores (p = 
0.49). Sixty-one youth in the control group completed the CGM-SE at baseline, and 58 youth 
completed the instrument at the 6-month visit. Youth without 6-month CGM-SE data either 
missed the 6-month visit or were not wearing the CGM and therefore did not complete the CGM-
SE.  
Table 8. CGM-SE score for control group at baseline and 6 months 
CGM-SE  Control Youth Control Parents 
Baseline n 
   Mean ± SD 
   Median (Range) 
   Score ≤ 80 (% participants) 
   Score > 80 (% participants) 
61 









6 month n 
   Mean ± SD 
   Median (Range) 
58 
          86 ± 12 
88 (50-100) 
49 
83 ± 15 
83 (20-100) 
Data reported as means ± SD, median (range), or % 
 
For parents, the baseline mean CGM-SE score was 84 ± 10 (62-100) compared to 83 ± 15 
for the 6 months score (Table 8 and Figure 4). There was no statistically significant difference 
observed between the parent baseline and 6 month CGM-SE scores (p = 0.96). At baseline, 60 
parents of the control youth completed the CGM-SE and at the 6-month visit, 49 parents 
completed the instrument. Parents with missing 6-month CGM self-efficacy data either had 
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youth who stopped wearing CGM and did not complete the instrument, or a patient visit was 
missed, or the parent who completed the CGM-SE at baseline was not the same parent who 
completed the instrument at 6 months. There was a statistically significant difference in youth 
CGM-SE scores according to CGM use at 3 and 6 months divided into 3 categories. Youth who 
wore CGM 0-≤48 hours/week at the 3 month visit had statistically significantly lower baseline 
CGM self-efficacy compared to youth who wore CGM >48-120 hours/week or >120 hours/week 
(80 ± 3 versus 88 ± 2 for both comparisons; p = 0.04 and p < 0.05, respectively) (Figure 5). 
Similarly, youth who wore CGM 0-≤48 hours/week at the 6 month visit had significantly lower 
baseline CGM self-efficacy (82 ± 2) compared to youth who wore CGM >48-120 hours/week 
(90 ± 2) (p = 0.03) or >120 hours/week 88 ± 2 (p = 0.08), which indicated a trend towards 
significance (Figure 6). Interestingly, parent baseline CGM-SE scores did not differ according to 
youth CGM use at either 3 or 6 months.  
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Figure 4. CGM-SE score distribution for control group parents at baseline and 6 months 
 
Figure 5. Baseline CGM-SE score (mean ± standard error) for youth and parents according to 3-
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Figure 6. Baseline CGM-SE score (mean ± standard error) for youth and parents according to 6 
month CGM use categories for control group participants. *p ≤ 0.05 
 
 
Spearman correlations showed a significant positive relationship between youth baseline 
and youth 6-month CGM-SE scores (r = 0.52, p < 0.0001), but this correlation was not 
statistically significant for parents (Table 9). Although youth and parent CGM-SE scores did not 
correlate for the control participants at baseline (r = 0.20, p = 0.13), a correlation was observed 
for the 6-month youth and parent scores (r = 0.36, p = 0.01). The higher parent baseline CGM-
SE score was correlated to higher baseline HbA1c (r = 0.32, p = 0.014), likely reflecting parental 
hopefulness for improvement. Additionally, the 6-month parent CGM-SE score correlated 
positively with CGM use at 3 months (r = 0.40, p = 0.005) and 6 months (r = 0.38, p = 0.008), 
which implies that parents are more confident if they know their child is wearing the device. 
There was also a significant positive correlation between the change in CGM-SE score for 
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which may support performance accomplishments or perceived mastery of a task as an 
instrumental source of self-efficacy.22 Surprisingly, these correlations were not significant for the 
change in youth CGM-SE score. T-tests did not reveal a statistically significant difference in 
baseline youth or parent self-efficacy scores for control participants from a 2-parent versus single 
parent home or those on insulin pump therapy versus multiple daily injections. 
Table 9. Correlations with control group youth and parent CGM-SE scores at baseline, 3 months, 
and 6 months. 









Age 0.20 0.12 -0.12 -0.13 
Diabetes duration 0.10    -0.23 0.03 -0.11 
HbA1c 
   Baseline 
   3 months 


















   Baseline 
   3 months 















  0.40* 
  0.38* 
CGM-SE Score Control Youth  
   Baseline 
   6 months 
 
- 
  0.52† 
 







  0.36* 
CGM-SE Score Control Parents 
   Baseline 













*p ≤ 0.05; †p < 0.0001 
 
To assess the predictive validity of the CGM-SE instruments, we examined CGM use and 
HbA1c after 3 and 6 months according to baseline CGM-SE scores. Youth who reported CGM-
SE scores > 80 used CGM statistically significantly more often at 3 and 6 months compared to 
youth with scores ≤ 80; 3 month CGM use: 110.1 ± 41.1 versus 70.8 ± 58.2 hours/week, 
respectively, (p = 0.005) and 6-month CGM use: 94.4 ± 50.7 hours/week versus 48.8 ± 56.7 
hours/week, respectively, (p = 0.004). Additionally, youth reporting higher baseline CGM self-
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efficacy had significantly lower HbA1c after 3 and 6 months compared with youth reporting 
lower CGM self-efficacy (3 month HbA1c: 7.5 ± 0.7% versus 8.3 ± 0.9%, p = 0.0004; 6 month 
HbA1c: 7.6 ± 0.7% versus 8.2 ± 0.9%, p = 0.02, respectively). These results indicate that youth 
who reported higher baseline CGM self-efficacy had greater CGM use at 3 and 6 months, as well 
as lower HbA1c at 3 and 6 months compared to youth with lower baseline CGM self-efficacy. 
Parent reported CGM self-efficacy did not predict youth CGM use or youth HbA1c at 3 or 6 
months.   
In a multivariate regression model (R2 = 0.13, p < 0.05) controlling for youth age and 
diabetes duration, youth CGM-SE score (p = 0.006) significantly predicted 3-month CGM use 
(Figure 7 and Table 10). Youth reporting CGM-SE scores > 80 used CGM 110.1 hours/week 
compared with 70.7 hours/week after 3 months for youth reporting CGM-SE scores ≤ 80 at 
baseline. The second multivariate model   (R2 = 0.14, p  < 0.05) also demonstrated that youth 
baseline CGM-SE score (p = 0.004) significantly predicted 6-month CGM use (Figure 7 and 
Table 10).  Youth reporting CGM-SE scores > 80 used CGM 94.7 hours/week compared with 
48.0 hours/week after 6 months for youth reporting CGM-SE scores ≤ 80 at baseline. 
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Table 10. Multivariate regression models 
DV R2 Model p Predictor β SE t p 
CGM use 
3 months 
0.13 <0.05  
Age£ 
Diabetes Duration£ 



















0.14 <0.05  
Age£ 
Diabetes Duration£ 



















0.22 0.003  
Age£ 
Diabetes Duration£ 



















0.11 0.08  
Age£ 
Diabetes Duration£ 


















¥Categorical	  variable	  due	  to	  findings	  in	  the	  bivariate	  analysis:	  CGM-­‐SE	  >80	  vs.	  ≤80	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Figure 7. 3- and 6-month CGM use (hours/week) (mean ± standard error) according to level of 
baseline youth CGM self-efficacy for control group participants. Blue bars = youth CGM-SE 
score ≤ 80. Red bars = youth CGM-SE score > 80. In multivariate models, baseline youth CGM-
SE score significantly predicted CGM use (hours/week) at 3 months (model: R2 = 0.13, p < 0.05) 
and at 6 months (model: R2 = 0.14, p < 0.05). 
 
Similarly, in a third multivariate model (R2 = 0.22, p = 0.003) controlling for youth age 
and diabetes duration, youth baseline CGM-SE score (p = 0.001) also significantly predicted 3 
month HbA1c (Figure 8 and Table 10). Youth reporting CGM-SE scores > 80 had 3 month 
HbA1c values of 7.5% compared with 8.3% for those reporting lower CGM-SE at baseline. A 
fourth multivariate model controlling for youth age and diabetes duration (R2 = 0.11, p = 0.08) 
demonstrated a trend towards significance with youth baseline CGM-SE score (p = 0.04) 
predicting 6 month HbA1c. Youth reporting CGM-SE scores > 80 had 6 month HbA1c value of 
7.6% compared with 8.1% for those reporting lower CGM-SE at baseline (Figure 8 and Table 
































s CGM-SE !80 CGM-SE >80 
3 months 
 
(p = 0.006) 
6 months 
 
(p = 0.004) 
	   93	  
score, and CGM use, youth baseline CGM-SE score (p = 0.003) significantly predicted 3 month 
HbA1c (R2 = 0.23, p = 0.0125), but youth baseline CGM-SE score (p = 0.16) did not 
significantly predict 6 month HbA1c (R2 = 0.16, p = 0.08) with CGM use in the model.  
These results indicate that youth who reported higher baseline CGM self-efficacy (score 
> 80) had greater CGM use and lower HbA1c at 3 and 6 months compared to youth with lower 
baseline CGM self-efficacy (score ≤ 80) supporting predictive validity. 
Figure 8. 3- and 6-month HbA1c (mean ± standard error) according to level of baseline youth 
CGM self-efficacy for control group participants. Blue bars = youth CGM-SE score ≤ 80. Red 
bars = youth CGM-SE score > 80. In multivariate models, baseline youth CGM-SE score 
significantly predicted HbA1c at 3 months (model: R2 = 0.22, p = 0.003) and with a trend 
towards significance at 6 months (model: R2 = 0.11, p = 0.08). 
 
Conclusions 
CGM technologies remain an underutilized approach to improving glycemic control in 
children and adolescents with type 1 diabetes.133,134 Although youth may initiate CGM, many 
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(p = 0.04) 
3 months 
 
(p = 0.001) 
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CGM devices,135-138 where ongoing BG monitoring is required for CGM calibration and as well 
as for confirmation of glucose levels prior to initiating treatments for either high or low glucose 
readings. Nonetheless, CGM technologies offer opportunities to improve glycemic control while 
avoiding severe hypoglycemia.17,139,140 Therefore, there remains a need to identify approaches to 
increase uptake and durability of CGM use, especially in the pediatric population. The current 
study identified the opportunity to utilize perceived self-efficacy related to CGM use in both 
children and adolescents with type 1 diabetes. The CGM-SE surveys demonstrated adequate 
psychometric properties for both the youth and parents versions while only the youth versions, 
for those ages 8-12 as well as for those 13 and older, had significant predictive value for CGM 
use 3 and 6 months after initiation. 
Specifically, the psychometric evaluation provided support for the reliability and validity 
of the CGM-SE. The instruments had good item-to-total correlations, which supported 
interrelatedness of the items.112 The CGM-SE also demonstrated high internal consistency for 
youth and parents, which established equivalence reliability or that all items in the instrument 
reliably measured the concept of interest.105 Factor analysis performed for the 11-item youth and 
14-item parent versions yielded two unique factors for each of the instruments respectively. The 
CGM-SE was developed to measure self-efficacy related to behavioral and technical aspects of 
CGM wear. The two factors identified for the parent version, which consisted of factor 1 
“relational” and factor 2 “technical”, reflect the intent of the instrument from a theoretical and 
conceptual perspective.132 While the items of the youth version also assessed behavioral and 
technical aspects of self-efficacy related to CGM wear, the factor analysis and inductive process 
of labeling the factors resulted in a factor identified as “away” and a factor identified as “home”, 
	   95	  
providing a context for the environment of the behavioral and technical aspects of CGM wear for 
the youth. 
While baseline youth CGM-SE scores were not related to age, diabetes duration, HbA1c, 
or BG monitoring frequency, there was a statistically significant inverse relationship between 
self-efficacy scores and mean blood glucose levels, suggesting that youth with lower blood 
glucose levels seem to have greater confidence in their use of CGM. Although the literature has 
reported that greater general diabetes self-efficacy is associated with diabetes management 
adherence and BG monitoring, 27,28,30,83 we found no relationships between youth-reported self-
efficacy and the diabetes adherence questionnaire, depression, or anxiety instruments. However, 
there was a statistically significant positive association between self-efficacy reported by teens 
and general quality of life, inferring a possible relationship between self-confidence in diabetes 
management and quality of life for teens with type 1 diabetes.  
Parent CGM-SE scores had a significant positive relationship to youth HbA1c and an 
inverse relationship to youth age at diagnosis. These findings suggest that parents of youth with 
higher HbA1c levels report greater confidence in their child’s use of CGM, possibly reflecting 
parental hopefulness for improvements in their child’s glycemic control with new advances such 
as CGM. Not surprisingly, parent CGM-SE scores were also significantly related to parent 
reported diabetes management adherence and the parent proxy report of their child’s diabetes 
specific quality of life.  
In assessment of the predictive validity of the CGM-SE, only the youth-reported CGM-
SE scores were significantly related to future CGM use and glycemic control. Youth who 
reported higher baseline CGM-SE score (> 80) had statistically significantly greater CGM use at 
3 and 6 months compared to those youth with lower scores. Similarly, youth with higher baseline 
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CGM-SE scores (> 80) had lower HbA1c at 3 and 6 months compared to those youth with lower 
scores. Multiple regression analyses also revealed that youth baseline CGM-SE score was a 
statistically significant predictor of 3 and 6 month CGM use with a higher self-efficacy score 
predicting greater CGM use. Similarly, higher youth baseline CGM self-efficacy significantly 
predicted 3 month HbA1c with a trend towards significance at 6 months with a higher score 
predicting a lower HbA1c. The parent CGM-SE survey did not demonstrate the same predictive 
validity for pediatric CGM use, likely because the parent version assesses the parent’s 
confidence in helping their child use CGM as well as their confidence in their child’s ability to 
use CGM. 
Overall, youth and parents reported high levels of self-efficacy related to CGM with 
youth and parent scores correlating for the control group analysis at 6 months. Surprisingly, 
youth with a lower HbA1c, from a 2-parent home, and using insulin pump therapy did not report 
higher self-efficacy related to CGM use despite the potential for a higher level of support at 
home, as well as increased attention for living with and managing the disease.  
Importantly, this study revealed that youth CGM self-efficacy does predict CGM wear 
and improvement in glycemic control over a 6 month time period. This finding coincides with 
Bandura’s theoretical model that self-efficacy is an important determinant of behavior, and 
greater self-efficacy translates to effort expended by an individual over a duration of time in the 
face of challenging circumstances.22 This finding is pertinent given the known challenges that 
youth with type 1 diabetes face in wearing CGM technologies and achieving target glycemic 
control. Assessing self-efficacy at the onset of CGM use may be important for the 
multidisciplinary diabetes team to consider. In particular, youth who report low-self-efficacy at 
the start of CGM, with CGM-SE scores ≤ 80, likely warrant greater education and support for 
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CGM implementation for these youth to succeed with durable CGM use over time. Identifying 
ways to decrease the burden of new technologies like CGM and the artificial pancreas may 
enhance patients’ self-confidence in their use. As the current artificial pancreas systems require 
substantial patient input,141 their use will likely also benefit from an understanding of self-
efficacy. 
There are caveats to these analyses. Only the control group from the larger 2-year RCT 
was evaluated in this study to determine predictive validity of CGM-SE at baseline. It is not 
known how a behavioral intervention to support CGM use may influence the construct of CGM 
self-efficacy over time, the aim of the larger ongoing RCT. The factor analysis performed for the 
youth instrument combined the uniform youth items 1-11 and did not include the additional 
items on the 13+ version because of the small sample size. Future psychometric analysis should 
evaluate the instruments in larger samples. Furthermore, the study included a relatively small 
sample size of homogeneous young patients with type 1 diabetes. Additionally, all patients 
received intensive insulin therapy, and the overwhelming majority received pump therapy. 
Future assessments of the CGM-SE instruments can include more diverse populations. As the 
larger study of this evaluation was aimed at implementing CGM in a pediatric sample, it is not 
surprising that the patients had to demonstrate acceptance and use of intensive insulin therapy 
prior to starting CGM. Nonetheless, although the patients were all intensively treated and desired 
to start CGM by virtue of their agreement to enter the 2-year RCT, a number of patients in the 
control group had already reduced their use of CGM after only 6 months of implementing the 
device. Additionally, only data through the 6-month time point were available for this study. 
Additional follow-up will be needed to determine how CGM self-efficacy affects longer-term 
CGM use. Future research will be needed to assess changes in self-efficacy over time, in addition 
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to determining if and how behavioral interventions to overcome barriers to CGM use affect 
CGM self-efficacy. Evaluation of the performance of the parent CGM-SE survey only included 
youth aged 8-17; assessment in parents of patients under 8 years old is also needed, especially 
given the challenge associated with CGM use in this pediatric population.142,143 Further work 
could also evaluate whether a change in device (e.g. a transition from the Dexcom SEVEN Plus 
to the Dexcom G4) affects self-efficacy and CGM outcomes. 
Finally, future work should include dyadic analyses to take into account the different 
viewpoints from the youth and the parent related to the various study measures (i.e. QOL, DMQ) 
that assess different aspects of diabetes management and psychosocial constructs, including self-
efficacy. Further research also could evaluate how self-efficacy may relate to outcome 
expectations pertaining to CGM use in youth with type 1 diabetes. Since both self-efficacy and 
outcome expectations are integral components of the behavior change process, identifying 
whether a relationship exists between these two constructs and CGM use would be pertinent.  
 In summary, the CGM-SE instruments for youth and parents demonstrate adequate 
psychometric properties for assessing confidence in using CGM. In addition, the youth CGM-SE 
instruments demonstrated significant predictive validity for future CGM use and glycemic 
control but the parent CGM-SE did not. Indeed, durable pediatric CGM use remains dependent 
on the child rather than on the parent. Thus, the youth CGM-SE instruments provide a method of 
assessing youth CGM self-efficacy in both research and clinical settings as efforts continue to 
address ways to increase uptake and to sustain use of CGM in pediatric populations with type 1 
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Chapter 5: Summary and Conclusions 
Synthesis 
 The three manuscripts of this dissertation evaluate CGM use and the role of self-efficacy 
in the pediatric population with type 1 diabetes. The literature has demonstrated the challenges of 
RT-CGM use in youth with type 1 diabetes, as well as the potential benefits of glycemic control. 
Given the documented difficulties of consistent CGM use in youth, it is important to explore 
barriers and facilitators of this technology. The work of this dissertation focuses on attributes of 
the youth experience with type 1 diabetes in the current era of diabetes technologies.  
 Masked CGM provides an alternative to RT-CGM, with the potential for improvement in 
glycemic control. While patients and providers eagerly await the reality of the AP as the future 
of advanced diabetes therapies, it is important to provide patients with therapy options that can 
help them transition to sensor technology. Masked CGM may provide such a transition with 
potential benefits, as described in manuscript one (Chapter 2) of this dissertation. Moreover, this 
research highlights the importance of the multidisciplinary diabetes team, in particular, the role 
of the nurse educator in equipping youth with knowledge to wear the device and 
recommendations to improve self-management following sensor wear.  
 Self-efficacy is also fundamental to health behavior change and an important component 
of self-management in patients with chronic diseases.24 A youth’s confidence or perceived ability 
to carry out diabetes tasks, especially in difficult situations, is significant for the diabetes team to 
recognize and foster. The second manuscript (Chapter 3) of this dissertation is an integrative 
review of instruments to measure self-efficacy in youth with T1D and their caregivers. Chapter 3 
identified that self-efficacy is a meaningful construct to measure in relation to key behaviors in 
general diabetes self-management. Self-efficacy, as it relates to the use of CGM, is particularly 
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relevant in the current era of diabetes technologies, given the challenges youth have with 
consistent CGM wear. Despite the importance of self-efficacy, few instruments are available to 
measure this construct within the domain of CGM therapy.  The third manuscript (Chapter 4) of 
this dissertation addresses this gap by exploring the psychometric properties of a novel CGM 
self-efficacy instrument. This study reports the results of a psychometric evaluation of a CGM 
self-efficacy instrument, which may prove useful for both clinicians and research teams focused 
on measuring self-efficacy in the contemporary era of diabetes technologies. This study revealed 
that self-efficacy related to CGM use in youth and parents may provide an important indicator of 
CGM success. The results demonstrated that self-efficacy related to CGM at baseline predicted 
CGM use and glycemic control at 3 and 6 months in a cohort of youth with type 1 diabetes who 
were initiating CGM therapy. Similar to the results in manuscript two (Chapter 3), this final 
manuscript identified that, in youth and families, self-efficacy may bolster self-management 
related to diabetes technologies and subsequent successful CGM adherence.  
Limitations 
 There are caveats to each of the studies reported in this dissertation. For the first 
manuscript, youth wore the masked CGM at only one time point with an evaluation of the 
proximal HbA1c pre masked CGM wear and 2-3 months post masked CGM to determine the 
effect of masked CGM on glycemic control. Also, although treatment recommendations 
involving advanced blousing and attending to active insulin resulted in significantly higher odds 
of improvement in HbA1c, the study did not investigate the longitudinal effect of masked CGM 
use on glycemic outcomes over time. Further research also could explore whether adherence to 
those treatment recommendations relates to HbA1c improvement, since adherence was not 
assessed in this observational descriptive study. Additionally, in this study, participants received 
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the review of the sensor data and treatment recommendations either over the phone or in clinic. 
This difference in mode of data review is another limitation because the study did not control for 
this difference. 
 The second manuscript, an integrative review of self-efficacy instruments in youth with 
type 1 diabetes, also had limitations. While this study consisted of a thorough review of the 
extant literature from the past decade (2003-2013), the study may not have identified relevant 
self-efficacy instruments discussed in publications before 2003. Furthermore, not all identified 
self-efficacy instruments were publically available; thus, not all survey items could be assessed. 
This caveat is relevant because the study concluded that more instruments are necessary to 
measure self-efficacy related to advancements in diabetes technologies. 
 Lastly, the final study, which evaluated a novel instrument to measure CGM self-efficacy 
in a contemporary cohort of youth, only included participant data from baseline through the 6-
month time point in a relatively small sample of homogeneous youth with T1D. The larger 2-
year RCT will provide further results pertaining to outcomes over a longer duration of time.  
Next Steps  
 This dissertation provides preliminary data towards the overall long-term research goal of 
optimizing self-efficacy in youth with type 1 diabetes in the current era of diabetes-related 
technological advances. Adherence to diabetes self-care tasks, particularly as they pertain to 
CGM technology, is challenging for the pediatric population with type 1 diabetes. Identifying 
elements such as self-efficacy that may promote and improve self-management behaviors is an 
important step toward improving diabetes outcomes and the consistent use of CGM technology.  
 The findings from the initial observational study in this dissertation, which used data 
obtained retrospectively from the electronic medical record, support the benefit of masked CGM 
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use in youth with type 1 diabetes. Because it has the potential to fine-tune glycemic control, 
masked CGM is an option the multidisciplinary diabetes team can provide to the youth and 
family to target glycemic control. While intermittent use of this technology may be less 
burdensome than continuous use of CGM, it is important to explore whether repeated masked 
CGM use and execution of the recommended therapy change one’s self-management and affect 
HbA1c long-term.  Additionally, masked CGM may provide a bridge in youth and families 
contemplating the transition to RT-CGM. Future work could investigate if patients who do a 
preliminary trial of masked CGM have more consistent and sustained use of RT-CGM as 
compared to patients who transition to RT-CGM therapy without prior CGM exposure. This 
would help identify whether routine masked CGM is an important first step in successful CGM 
initiation. 
 The second manuscript identified the apparent need for new instruments to measure self-
efficacy in friends or peers of youth with type 1 diabetes in addition to instruments related to 
diabetes technologies. Since social support and the peer network are pivotal components of a 
child’s development and may be integral to diabetes management, future studies could evaluate 
how diabetes self-efficacy from a friend/peer perspective may influence a youth’s type 1 diabetes 
self-management. 
In the last manuscript of this dissertation, establishing the psychometrics of the novel 
CGM-SE instrument and its correlation to CGM utility provides a basis for (a) the use of this 
instrument in future evidence based research with type 1 diabetes youth from various populations 
and (b) future hypothesis generation and testing in intervention-based studies that focus on the 
concept of self-efficacy in youth with type 1 diabetes who use CGM technology. Identifying if 
self-efficacy can predict CGM use will help guide future research efforts and hypothesis testing 
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related to CGM use, self-efficacy, and optimal health outcomes in youth with type 1 diabetes. 
Additionally, diabetes technologies continue to advance. The closed-loop AP project is at the 
forefront of such advances. While the AP project brings promise of significant lifestyle and 
glycemic improvements, evaluating how the AP may affect psychosocial correlates is just as 
important as the continued work to refine this technology. Future research and clinical efforts 
could utilize the self-efficacy instrument described in the third manuscript of this dissertation to 
evaluate patient confidence related to use of AP technology. 
Bandura’s SCT, and particularly his model of self-efficacy, should guide further studies 
exploring this construct related to diabetes technologies and behavior change. According to 
Bandura, four sources influence an individual’s efficacy expectations including performance 
accomplishments, vicarious experiences, verbal persuasion, and emotional arousal.22 Intervention 
research could target these unique areas to determine the effect on self-efficacy related to CGM 
wear. Specifically, as mentioned above, studies could investigate whether a trial of masked CGM 
wear prior to RT-CGM (performance accomplishments) strengthens CGM self-efficacy and 
subsequent adherence to RT-CGM technology. Research also could focus on preliminary CGM 
education to determine whether modeling of CGM use by youth already wearing CGM 
(vicarious experience) or nurse educator support/suggestion (verbal persuasion) may influence 
CGM self-efficacy in youth initiating this technology. Finally, multidisciplinary team research 
could incorporate psychologists in initial CGM education to discuss stressors or fears pertaining 
to CGM (emotional arousal) in an effort to desensitize anxiety that individuals may feel with 
trying a new device. Since there are multiple components that affect self-efficacy, research may 
benefit from concentrating on these various influences. 
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Contribution to Science and Nursing 
This body of work provides a greater understanding of the use of masked CGM 
technology, the concept of self-efficacy as it relates to youth with type 1 diabetes and their 
caregivers, and how to measure the concept of self-efficacy related to CGM use in a 
contemporary cohort of youth with type 1 diabetes.  Importantly, this dissertation contributes to 
the knowledge of the relationship of self-efficacy and CGM use. The research benefits youth 
with type 1 diabetes by establishing the utility of the CGM-SE survey, a novel self-efficacy 
instrument. The development and testing of this instrument address a pertinent gap in the 
literature related to measuring CGM self-efficacy and whether self-efficacy predicts CGM use in 
youth with type 1 diabetes.  
The results of this dissertation (a) add to the state of the science pertaining to CGM and 
factors that may affect its use and (b) facilitate the learning process for diabetes healthcare 
providers regarding the measurement of self-efficacy for youth with type 1 diabetes in the 
current era of diabetes technologies. Nurses and nurse researchers are fundamental to diabetes 
self-care and technology education. Their close proximity to the patients and families provides 
an exceptional opportunity to understand the barriers and facilitators of adherence and self-
efficacy as well as opportunities for improved outcomes, in particular, use of new diabetes 
technologies such as CGM. The nurse educator is central to the multidisciplinary diabetes team 
and serves as the hub of the medical home. To educate, support, and maintain an appropriate 
level of family-based diabetes management for youth with type 1 diabetes, it is essential for the 
nurse educator to understand how technologically advanced therapies affect glycemic control, 
self-management, and psychosocial attributes. 
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Use of the CGM-SE measure may enhance the ability of diabetes health care providers to 
identify youth at risk for suboptimal CGM adherence based on lower self-reported self-efficacy. 
Healthcare providers, particularly nurses, could then bolster resources to support at-risk youth. 
This research provides preliminary knowledge for further testing in studies related to self-
efficacy.  Ongoing efforts to establish a research knowledge base related to barriers and 
facilitators of CGM technology will allow the interdisciplinary team to refine evidence-based 
practices for youth with type 1 diabetes and, thus, target glycemic control more effectively in the 
current era of advanced diabetes technologies. 
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Appendix A: CGM-SE instrument youth 8-12 year old version 
  
 
CGMi Study Youth Surveys (MASTER)  ! Data Ent 1 | Init: __  Dt: __ /__ /__ 
Revised 01/25/12 9 ! Data Ent 2 | Init: __  Dt: __ /__ /__ 
SID: __ __ __ __    VISIT DATE: __ __  / __ __  / __ __    VISIT #:  __ __ 
SURVEY H (CSE) 
 
The following statements are about how confident you are with using a continuous glucose monitor (CGM). 
Having confidence means you think you can do something, whether or not you are doing it now. You may feel 
more confident in your ability to do some CGM tasks than others.  
 





















Wear a raincoat or carry an umbrella when it is 




















 1. Insert the CGM sensor (on my own or with my 
 parents’ help) ! " # $ % & ' 
 2. Calibrate the CGM sensor (on my own or with 
 my parents’ help) ! " # $ % & ' 
 3. Keep my CGM receiver with me ! " # $ % & ' 
 4. Look at my CGM receiver screen during the day ! " # $ % & ' 
 5. Respond to the CGM receiver alarms (on my 
 own or with my parents’ help) ! " # $ % & ' 
 6. Charge the CGM receiver (on my own or with 
 my  parents’ help) ! " # $ % & ' 
 7. Ask for help with using the CGM ! " # $ % & ' 
 8. Wear the CGM sensor at least 6 days a week ! " # $ % & ' 
 9. Talk to my parents if I am having a hard time 
 using the CGM ! " # $ % & ' 
 10. Respond to CGM alarms when I am at school ! " # $ % & ' 
 11. Respond to CGM alarms when I am with my 
 friends ! " # $ % & ' 
 
8-12 VERSION; completed at V2, not baseline 
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Appendix B: CGM-SE instrument youth 13+ version 
  
 
CGMi Study Youth Surveys (MASTER)  ! Data Ent 1 | Init: __  Dt: __ /__ /__ 
Revised 01/25/12 10 ! Data Ent 2 | Init: __  Dt: __ /__ /__ 
SID: __ __ __ __    VISIT DATE: __ __  / __ __  / __ __    VISIT #:  __ __ 
SURVEY H (CSE) 
 
The following statements are about how confident you are with using a continuous glucose monitor (CGM). 
Having confidence means you think you can do something, whether or not you are doing it now. You may feel 
more confident in your ability to do some CGM tasks than others.  
 





















Wear a raincoat or carry an umbrella when it is 




















 1. Insert the CGM sensor (on my own or with my 
 parents’ help) ! " # $ % & ' 
 2. Calibrate the CGM sensor (on my own or with 
 my parents’ help) ! " # $ % & ' 
 3. Keep my CGM receiver with me ! " # $ % & ' 
 4. Look at my CGM receiver screen during the day ! " # $ % & ' 
 5. Respond to the CGM receiver alarms (on my 
 own or with my parents’ help) ! " # $ % & ' 
 6. Charge the CGM receiver (on my own or with 
 my  parents’ help) ! " # $ % & ' 
 7. Ask for help with using the CGM ! " # $ % & ' 
 8. Wear the CGM sensor at least 6 days a week ! " # $ % & ' 
 9. Talk to my parents if I am having a hard time 
 using the CGM ! " # $ % & ' 
 10. Respond to CGM alarms when I am at school ! " # $ % & ' 
 11. Respond to CGM alarms when I am with my 
 friends ! " # $ % & ' 
 12. Download the CGM data (on my own or with 
 my parents’ help) ! " # $ % & ' 
 13. Problem-solve when having technical difficulties 
 with the sensor, transmitter, or receiver (on my 
 own or with my parents’ help) 
! " # $ % & ' 
 14. Adjust my insulin dose based on the real-time 
 CGM data (on my own or with my parents’ help) ! " # $ % & ' 
 15. Adjust my insulin dose based on the 
 downloaded CGM data (on my own or with my 
 parents’ help) 
! " # $ % & ' 
 
13+ VERSION; completed a  V2, not baseline
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Appendix C: CGM-SE parent version 
  
 
CGMi Study Parent Surveys (MASTER)  ! Data Ent 1 | Init: __  Dt: __ /__ /__ 
Revised 01/25/12 13 ! Data Ent 2 | Init: __  Dt: __ /__ /__ 
SID: __ __ __ __    VISIT DATE: __ __  / __ __  / __ __    VISIT #:  __ __ 
SURVEY H (CSE) 
 
The following statements are about how confident you are with using a continuous glucose monitor (CGM). 
Having confidence means you think you can do something, whether or not you are doing it now. You may feel 
more confident in your ability to do some CGM tasks than others.  
 




















 1. Insert the CGM sensor ! " # $ % & ' 
 2. Work with my child to calibrate the CGM 
 sensor, even if he/she does not want to ! " # $ % & ' 
 3. Work with my child to keep the CGM receiver 
 with him/her ! " # $ % & ' 
 4. Work with my child to look at his/her CGM 
 receiver screen during the day ! " # $ % & ' 
 5. Work with my child to respond to the CGM 
 receiver alarms ! " # $ % & ' 
 6. Ensure the CGM receiver stays charged ! " # $ % & ' 
 7. Speak with my child’s medical team if I need 
 help with the CGM ! " # $ % & ' 
 8. Download the CGM data ! " # $ % & ' 
 9. Problem-solve when having technical difficulties 
 with the sensor, transmitter, or receiver ! " # $ % & ' 
 10. Adjust my child’s insulin dose based on the 
 real-time CGM data ! " # $ % & ' 
 11. Adjust my child’s insulin dose based on the 
 downloaded CGM data ! " # $ % & ' 
 12. Share the CGM responsibilities with my child ! " # $ % & ' 
 13. Work with my child to wear the CGM sensor 
 every day ! " # $ % & ' 
 14. Be encouraging and supportive when working 






Completed at V2, not baseline 
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